Protein O-GlcNAcylation in Health and Diseases

Zhihong Ran; Chuanbao Chen; Jingfeng Ou; Guanyi Wu; Chao Yang; Xiaoyou Liu

doi:10.1002/mco2.70536

MedComm ›› 2025, Vol. 6 ›› Issue (12) :e70536 DOI: 10.1002/mco2.70536

REVIEW

Protein O-GlcNAcylation in Health and Diseases

Author information +

History +

PDF

Abstract

O-GlcNAcylation is a reversible posttranslational modification of proteins that has garnered significant attention in recent years. By regulating the structure and function of proteins, it plays a critical role in various biological processes. Normal O-GlcNAcylation is essential for maintaining internal homeostasis and is involved in controlling fundamental biological events such as gene expression, the cell cycle regulation, metabolism, and signal transduction. Conversely, aberrant O-GlcNAcylation is closely linked to the onset and progression of various diseases—including neurodegenerative diseases, cancers, cardiovascular diseases, and immune-related diseases—where it drives pathological development. Currently, there is a lack of comprehensive reviews systematically addressing the specific mechanisms of O-GlcNAcylation under both physiological and pathological conditions. Therefore, this article aims to summarize its dual role in maintaining organismal homeostasis and promoting disease pathogenesis, providing an integrated evaluation of the biological significance of this modification in health and diseases. Furthermore, it discusses the potential of O-GlcNAcylation as a therapeutic target, explores its clinical applications, and analyzes the current challenges and future directions in drug development, thereby offering theoretical insights and research perspectives for related fields.

Keywords

biological processes / diseases / health / mechanisms / O-GlcNAcylation / therapy

Cite this article

Download citation ▾

Zhihong Ran, Chuanbao Chen, Jingfeng Ou, Guanyi Wu, Chao Yang, Xiaoyou Liu. Protein O-GlcNAcylation in Health and Diseases. MedComm, 2025, 6(12): e70536 DOI:10.1002/mco2.70536

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	C. R. Torres and G. W. Hart, “Topography and Polypeptide Distribution of Terminal N-Acetylglucosamine Residues on the Surfaces of Intact Lymphocytes. Evidence for O-Linked Glcnac,” Journal of Biological Chemistry 259, no. 5 (1984): 3308–3317, https://doi.org/10.1016/S0021-9258(17)43295-9.

[2]	G. W. Hart, M. P. Housley, and C. Slawson, “Cycling of O-Linked Beta-N-Acetylglucosamine on Nucleocytoplasmic Proteins,” Nature 446, no. 7139 (2007): 1017–1022, https://doi.org/10.1038/nature05815.

[3]	C. M. Joiner, H. Li, J. Jiang, et al., “Structural Characterization of the O-Glcnac Cycling Enzymes: Insights into Substrate Recognition and Catalytic Mechanisms,” Current Opinion in Structural Biology 56 (2019): 97–106, https://doi.org/10.1016/j.sbi.2018.12.003.

[4]

L. K. Kreppel, M. A. Blomberg, and G. W. Hart, “Dynamic Glycosylation of Nuclear and Cytosolic Proteins. Cloning and Characterization of a Unique O-Glcnac Transferase With Multiple Tetratricopeptide Repeats,” Journal of Biological Chemistry 272, no. 14 (1997): 9308–9315, https://doi.org/10.1074/jbc.272.14.9308.

[5]	W. A. Lubas, D. W. Frank, M. Krause, et al., “O-Linked Glcnac Transferase Is a Conserved Nucleocytoplasmic Protein Containing Tetratricopeptide Repeats,” Journal of Biological Chemistry 272, no. 14 (1997): 9316–9324, https://doi.org/10.1074/jbc.272.14.9316.

[6]	G. W. Hart, C. Slawson, G. Ramirez-Correa, et al., “Cross Talk between O-Glcnacylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic Disease,” Annual Review of Biochemistry 80 (2011): 825–858, https://doi.org/10.1146/annurev-biochem-060608-102511.

[7]	G. W. Hart, M. P. Housley, and C. Slawson, “Cycling of O-Linked Beta-N-Acetylglucosamine on Nucleocytoplasmic Proteins,” Nature 446, no. 7139 (2007): 1017–1022, https://doi.org/10.1038/nature05815.

[8]	M. Joud, M. Moller, and M. L. Olsson, “Identification of Human Glycosyltransferase Genes Expressed in Erythroid Cells Predicts Potential Carbohydrate Blood Group Loci,” Scientific Reports 8, no. 1 (2018): 6040, https://doi.org/10.1038/s41598-018-24445-5.

[9]	K. J. Karczewski, L. C. Francioli, G. Tiao, et al., “The Mutational Constraint Spectrum Quantified from Variation in 141,456 Humans,” Nature 581, no. 7809 (2020): 434–443, https://doi.org/10.1038/s41586-020-2308-7.

[10]	M. Resto, B. Kim, A. G. Fernandez, et al., “O-Glcnacase Is an Rna Polymerase II Elongation Factor Coupled to Pausing Factors Spt5 and Tif1Beta,” Journal of Biological Chemistry 291, no. 43 (2016): 22703–22713, https://doi.org/10.1074/jbc.M116.751420.

[11]

D. C. Love, S. Ghosh, M. A. Mondoux, et al., “Dynamic O-Glcnac Cycling at Promoters of Caenorhabditis Elegans Genes Regulating Longevity, Stress, and Immunity,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 16 (2010): 7413–7418, https://doi.org/10.1073/pnas.0911857107.

[12]	D. C. Love and J. A. Hanover, “The Hexosamine Signaling Pathway: Deciphering the “O-Glcnac Code”,” Science Stke no. 312 (2005): re13.

[13]	L. Wells, Y. Gao, J. A. Mahoney, et al., “Dynamic O-Glycosylation of Nuclear and Cytosolic Proteins: Further Characterization of the Nucleocytoplasmic Beta-N-Acetylglucosaminidase, O-Glcnacase,” Journal of Biological Chemistry 277, no. 3 (2002): 1755–1761, https://doi.org/10.1074/jbc.M109656200.

[14]	X. Li, W. Gong, H. Wang, et al., “O-Glcnac Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3,” Immunity 50, no. 3 (2019): 576–590, https://doi.org/10.1016/j.immuni.2019.01.007.

[15]	S. Hardiville and G. W. Hart, “Nutrient Regulation of Signaling, Transcription, and Cell Physiology by O-Glcnacylation,” Cell Metabolism 20, no. 2 (2014): 208–213, https://doi.org/10.1016/j.cmet.2014.07.014.

[16]	S. Wei, Q. Zhao, K. Zheng, et al., “Gfat1-Linked Tab1 Glutamylation Sustains P38 Mapk Activation and Promotes Lung Cancer Cell Survival under Glucose Starvation,” Cell Discovery 8, no. 1 (2022): 77, https://doi.org/10.1038/s41421-022-00423-0.

[17]	G. W. Hart, C. Slawson, G. Ramirez-Correa, et al., “Cross Talk between O-Glcnacylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic Disease,” Annual Review of Biochemistry 80 (2011): 825–858, https://doi.org/10.1146/annurev-biochem-060608-102511.

[18]	G. W. Hart, M. P. Housley, and C. Slawson, “Cycling of O-Linked Beta-N-Acetylglucosamine on Nucleocytoplasmic Proteins,” Nature 446, no. 7139 (2007): 1017–1022, https://doi.org/10.1038/nature05815.

[19]	J. A. Groves, A. Lee, G. Yildirir, et al., “Dynamic O-Glcnacylation and Its Roles in the Cellular Stress Response and Homeostasis,” Cell Stress & Chaperones 18, no. 5 (2013): 535–558, https://doi.org/10.1007/s12192-013-0426-y.

[20]	Y. H. Chang, C. L. Weng, and K. I. Lin, “O-Glcnacylation and Its Role in the Immune System,” Journal of Biomedical Science 27, no. 1 (2020): 57, https://doi.org/10.1186/s12929-020-00648-9.

[21]	Y. R. Yang, M. Song, H. Lee, et al., “O-Glcnacase Is Essential for Embryonic Development and Maintenance of Genomic Stability,” Aging Cell 11, no. 3 (2012): 439–448, https://doi.org/10.1111/j.1474-9726.2012.00801.x.

[22]	N. O'Donnell, N. E. Zachara, G. W. Hart, et al., “Ogt-Dependent X-Chromosome-Linked Protein Glycosylation Is a Requisite Modification in Somatic Cell Function and Embryo Viability,” Molecular and Cellular Biology 24, no. 4 (2004): 1680–1690, https://doi.org/10.1128/MCB.24.4.1680-1690.2004.

[23]

R. Shafi, S. P. Iyer, L. G. Ellies, et al., “The O-Glcnac Transferase Gene Resides on the X Chromosome and Is Essential for Embryonic Stem Cell Viability and Mouse Ontogeny,” Proceedings of the National Academy of Sciences of the United States of America 97, no. 11 (2000): 5735–5739, https://doi.org/10.1073/pnas.100471497.

[24]	Y. R. Yang, M. Song, H. Lee, et al., “O-Glcnacase Is Essential for Embryonic Development and Maintenance of Genomic Stability,” Aging Cell 11, no. 3 (2012): 439–448, https://doi.org/10.1111/j.1474-9726.2012.00801.x.

[25]	T. Wang, K. Birsoy, N. W. Hughes, et al., “Identification and Characterization of Essential Genes in the Human Genome,” Science 350, no. 6264 (2015): 1096–1101, https://doi.org/10.1126/science.aac7041.

[26]	S. Hardiville and G. W. Hart, “Nutrient Regulation of Gene Expression by O-Glcnacylation of Chromatin,” Current Opinion in Chemical Biology 33 (2016): 88–94, https://doi.org/10.1016/j.cbpa.2016.06.005.

[27]	X. F. He, X. Hu, G. J. Wen, et al., “O-Glcnacylation in Cancer Development and Immunotherapy,” Cancer Letters 566 (2023): 216258, https://doi.org/10.1016/j.canlet.2023.216258.

[28]	B. E. Lee, P. G. Suh, and J. I. Kim, “O-Glcnacylation in Health and Neurodegenerative Diseases,” Experimental and Molecular Medicine 53, no. 11 (2021): 1674–1682, https://doi.org/10.1038/s12276-021-00709-5.

[29]	X. F. He, X. Hu, G. J. Wen, et al., “O-Glcnacylation in Cancer Development and Immunotherapy,” Cancer Letters 566 (2023): 216258, https://doi.org/10.1016/j.canlet.2023.216258.

[30]	J. C. Chatham, J. Zhang, and A. R. Wende, “Role of O-Linked N-Acetylglucosamine Protein Modification in Cellular (Patho)Physiology,” Physiological Reviews 101, no. 2 (2021): 427–493, https://doi.org/10.1152/physrev.00043.2019.

[31]	Q. Zhu, L. Zhou, Z. Yang, et al., “O-Glcnacylation Plays a Role in Tumor Recurrence of Hepatocellular Carcinoma Following Liver Transplantation,” Medical Oncology 29, no. 2 (2012): 985–993, https://doi.org/10.1007/s12032-011-9912-1.

[32]	M. M. Mukherjee, D. Biesbrock, and J. A. Hanover, “Galectin-3: Integrator of Signaling via Hexosamine Flux,” Biomolecules 15, no. 7 (2025), https://doi.org/10.3390/biom15071028.

[33]	Z. G. Levine and S. Walker, “The Biochemistry of O-Glcnac Transferase: Which Functions Make It Essential in Mammalian Cells?,” Annual Review of Biochemistry 85 (2016): 631–657, https://doi.org/10.1146/annurev-biochem-060713-035344.

[34]

[35]	S. Hardiville and G. W. Hart, “Nutrient Regulation of Signaling, Transcription, and Cell Physiology by O-Glcnacylation,” Cell Metabolism 20, no. 2 (2014): 208–213, https://doi.org/10.1016/j.cmet.2014.07.014.

[36]	B. A. Lewis and J. A. Hanover, “O-Glcnac and the Epigenetic Regulation of Gene Expression,” Journal of Biological Chemistry 289, no. 50 (2014): 34440–34448, https://doi.org/10.1074/jbc.R114.595439.

[37]	M. P. Parker, K. R. Peterson, and C. Slawson, “O-Glcnacylation and O-Glcnac Cycling Regulate Gene Transcription: Emerging Roles in Cancer,” Cancers 13, no. 7 (2021), https://doi.org/10.3390/cancers13071666.

[38]	S. M. Ranuncolo, S. Ghosh, J. A. Hanover, et al., “Evidence of the Involvement of O-Glcnac-Modified Human Rna Polymerase II Ctd in Transcription in Vitro and in Vivo,” Journal of Biological Chemistry 287, no. 28 (2012): 23549–23561, https://doi.org/10.1074/jbc.M111.330910.

[39]	B. A. Lewis, A. L. Burlingame, and S. A. Myers, “Human Rna Polymerase II Promoter Recruitment in Vitro Is Regulated by O-Linked N-Acetylglucosaminyltransferase (Ogt),” Journal of Biological Chemistry 291, no. 27 (2016): 14056–14061, https://doi.org/10.1074/jbc.M115.684365.

[40]	K. Sakabe, Z. Wang, and G. W. Hart, “Beta-N-Acetylglucosamine (O-Glcnac) Is Part of the Histone Code,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 46 (2010): 19915–19920, https://doi.org/10.1073/pnas.1009023107.

[41]

S. Zhang, K. Roche, H. Nasheuer, et al., “Modification of Histones by Sugar Beta-N-Acetylglucosamine (Glcnac) Occurs on Multiple Residues, Including Histone H3 Serine 10, and Is Cell Cycle-Regulated,” Journal of Biological Chemistry 286, no. 43 (2011): 37483–37495, https://doi.org/10.1074/jbc.M111.284885.

[42]	J. J. Fong, B. L. Nguyen, R. Bridger, et al., “Beta-N-Acetylglucosamine (O-Glcnac) Is a Novel Regulator of Mitosis-Specific Phosphorylations on Histone H3,” Journal of Biological Chemistry 287, no. 15 (2012): 12195–12203, https://doi.org/10.1074/jbc.M111.315804.

[43]	Q. Chen, Y. Chen, C. Bian, et al., “Tet2 Promotes Histone O-Glcnacylation during Gene Transcription,” Nature 493, no. 7433 (2013): 561–564, https://doi.org/10.1038/nature11742.

[44]	Q. Xu, C. Yang, Y. Du, et al., “Ampk Regulates Histone H2B O-Glcnacylation,” Nucleic Acids Research 42, no. 9 (2014): 5594–5604, https://doi.org/10.1093/nar/gku236.

[45]	A. Delporte, J. De Zaeytijd, N. De Storme, et al., “Cell Cycle-Dependent O-Glcnac Modification of Tobacco Histones and Their Interaction With the Tobacco Lectin,” Plant Physiology and Biochemistry 83 (2014): 151–158, https://doi.org/10.1016/j.plaphy.2014.07.021.

[46]	V. Dehennaut, D. Leprince, and T. Lefebvre, “O-Glcnacylation, an Epigenetic Mark. Focus on the Histone Code, Tet Family Proteins, and Polycomb Group Proteins,” Frontiers in Endocrinology 5 (2014): 155, https://doi.org/10.3389/fendo.2014.00155.

[47]	P. Wang, C. Peng, X. Liu, et al., “Ogt Mediated Histone H2B S112 Glcnacylation Regulates Dna Damage Response,” Journal of Genetics and Genomics 42, no. 9 (2015): 467–475, https://doi.org/10.1016/j.jgg.2015.07.002.

[48]	M. Leturcq, T. Lefebvre, and A. Vercoutter-Edouart, “O-Glcnacylation and Chromatin Remodeling in Mammals: An up-to-Date Overview,” Biochemical Society Transactions 45, no. 2 (2017): 323–338, https://doi.org/10.1042/BST20160388.

[49]	R. Fujiki, W. Hashiba, H. Sekine, et al., “Glcnacylation of Histone H2B Facilitates Its Monoubiquitination,” Nature 480, no. 7378 (2011): 557–560, https://doi.org/10.1038/nature10656.

[50]	S. Hardiville, P. S. Banerjee, E. S. Selen Alpergin, et al., “Tata-Box Binding Protein O-Glcnacylation at T114 Regulates Formation of the B-Tfiid Complex and Is Critical for Metabolic Gene Regulation,” Molecular Cell 77, no. 5 (2020): 1143–1152, https://doi.org/10.1016/j.molcel.2019.11.022.

[51]	N. Noach, Y. Segev, I. Levi, et al., “Modification of Topoisomerase I Activity by Glucose and by O-Glcnacylation of the Enzyme Protein,” Glycobiology 17, no. 12 (2007): 1357–1364, https://doi.org/10.1093/glycob/cwm105.

[52]	M. Eustice, M. R. Bond, and J. A. Hanover, “O-Glcnac Cycling and the Regulation of Nucleocytoplasmic Dynamics,” Biochemical Society Transactions 45, no. 2 (2017): 427–436, https://doi.org/10.1042/BST20160171.

[53]	C. Butkinaree, K. Park, and G. W. Hart, “Extensive Crosstalk With Phosphorylation to Regulate Signaling and Transcription in Response to Nutrients and Stress,” Biochimica Et Biophysica Acta 1800, no. 2 (2010): 96–106, https://doi.org/10.1016/j.bbagen.2009.07.018.

[54]	S. Ozcan, S. S. Andrali, and J. E. L. Cantrell, “Modulation of Transcription Factor Function by O-Glcnac Modification,” Biochimica Et Biophysica Acta 1799, no. 5–6 (2010): 353–364, https://doi.org/10.1016/j.bbagrm.2010.02.005.

[55]	M. P. Housley, J. T. Rodgers, N. D. Udeshi, et al., “O-Glcnac Regulates Foxo Activation in Response to Glucose,” Journal of Biological Chemistry 283, no. 24 (2008): 16283–16292, https://doi.org/10.1074/jbc.M802240200.

[56]	M. Kuo, V. Zilberfarb, N. Gangneux, et al., “O-Glycosylation of Foxo1 Increases Its Transcriptional Activity towards the Glucose 6-Phosphatase Gene,” Febs Letters 582, no. 5 (2008): 829–834, https://doi.org/10.1016/j.febslet.2008.02.010.

[57]	Y. Fardini, E. Masson, O. Boudah, et al., “O-Glcnacylation of Foxo1 in Pancreatic Beta Cells Promotes Akt Inhibition Through an Igfbp1-Mediated Autocrine Mechanism,” Faseb Journal 28, no. 2 (2014): 1010–1021, https://doi.org/10.1096/fj.13-238378.

[58]	S. Choe, F. Ladam, and C. G. Sagerstrom, “Tale Factors Poise Promoters for Activation by Hox Proteins,” Developmental Cell 28, no. 2 (2014): 203–211, https://doi.org/10.1016/j.devcel.2013.12.011.

[59]	A. Draime, L. Bridoux, M. Belpaire, et al., “The O-Glcnac Transferase Ogt Interacts With and Post-Translationally Modifies the Transcription Factor Hoxa1,” Febs Letters 592, no. 7 (2018): 1185–1201, https://doi.org/10.1002/1873-3468.13015.

[60]	S. P. Jackson and R. Tjian, “O-Glycosylation of Eukaryotic Transcription Factors: Implications for Mechanisms of Transcriptional Regulation,” Cell 55, no. 1 (1988): 125–133, https://doi.org/10.1016/0092-8674(88)90015-3.

[61]	S. Lichtsteiner and U. Schibler, “A Glycosylated Liver-Specific Transcription Factor Stimulates Transcription of the Albumin Gene,” Cell 57, no. 7 (1989): 1179–1187, https://doi.org/10.1016/0092-8674(89)90055-X.

[62]	T. Y. Chou, G. W. Hart, and C. V. Dang, “C-Myc Is Glycosylated at Threonine 58, a Known Phosphorylation Site and a Mutational Hot Spot in Lymphomas,” Journal of Biological Chemistry 270, no. 32 (1995): 18961–18965, https://doi.org/10.1074/jbc.270.32.18961.

[63]	T. Y. Chou, C. V. Dang, and G. W. Hart, “Glycosylation of the C-Myc Transactivation Domain,” Proceedings of the National Academy of Sciences of the United States of America 92, no. 10 (1995): 4417–4421, https://doi.org/10.1073/pnas.92.10.4417.

[64]	A. J. Reason, H. R. Morris, M. Panico, et al., “Localization of O-Glcnac Modification on the Serum Response Transcription Factor,” Journal of Biological Chemistry 267, no. 24 (1992): 16911–16921, https://doi.org/10.1016/S0021-9258(18)41871-6.

[65]	F. I. Comer and G. W. Hart, “O-Glcnac and the Control of Gene Expression,” Biochimica Et Biophysica Acta 1473, no. 1 (1999): 161–171, https://doi.org/10.1016/S0304-4165(99)00176-2.

[66]	Z. Tan, G. Fei, J. A. Paulo, et al., “O-Glcnac Regulates Gene Expression by Controlling Detained Intron Splicing,” Nucleic Acids Research 48, no. 10 (2020): 5656–5669, https://doi.org/10.1093/nar/gkaa263.

[67]	R. Mathew, K. Hartmuth, S. Mohlmann, et al., “Phosphorylation of Human Prp28 by Srpk2 Is Required for Integration of the U4/U6-U5 Tri-Snrnp into the Spliceosome,” Nature Structural & Molecular Biology 15, no. 5 (2008): 435–443, https://doi.org/10.1038/nsmb.1415.

[68]	H. Y. Wang, W. Lin, J. A. Dyck, et al., “Srpk2: A Differentially Expressed Sr Protein-Specific Kinase Involved in Mediating the Interaction and Localization of Pre-Mrna Splicing Factors in Mammalian Cells,” Journal of Cell Biology 140, no. 4 (1998): 737–750, https://doi.org/10.1083/jcb.140.4.737.

[69]	W. Tan, P. Jiang, W. Zhang, et al., “Posttranscriptional Regulation of De Novo Lipogenesis by Glucose-Induced O-Glcnacylation,” Molecular Cell 81, no. 9 (2021): 1890–1904, https://doi.org/10.1016/j.molcel.2021.02.009.

[70]	Y. Bi, Z. Deng, W. Ni, et al., “Arabidopsis Acinus Is O-Glycosylated and Regulates Transcription and Alternative Splicing of Regulators of Reproductive Transitions,” Nature Communications 12, no. 1 (2021): 945, https://doi.org/10.1038/s41467-021-20929-7.

[71]	M. Zhao, X. Yao, P. Wei, et al., “O-Glcnacylation of Tdp-43 Suppresses Proteinopathies and Promotes Tdp-43'S Mrna Splicing Activity,” Embo Reports 22, no. 6 (2021): e51649, https://doi.org/10.15252/embr.202051649.

[72]	J. Wang, N. Liu, X. Wei, et al., “Regulation of Auf1 Alternative Splicing by Hnrnpa1 and Srsf2 Modulate the Sensitivity of Ovarian Cancer Cells to Cisplatin,” Cellular Oncology 47, no. 6 (2024): 2349–2366, https://doi.org/10.1007/s13402-024-01023-8.

[73]	Q. Zeidan, Z. Wang, A. De Maio, et al., “O-Glcnac Cycling Enzymes Associate With the Translational Machinery and Modify Core Ribosomal Proteins,” Molecular Biology of the Cell 21, no. 12 (2010): 1922–1936, https://doi.org/10.1091/mbc.e09-11-0941.

[74]	G. W. Hart, “Nutrient Regulation of Signaling and Transcription,” Journal of Biological Chemistry 294, no. 7 (2019): 2211–2231, https://doi.org/10.1074/jbc.AW119.003226.

[75]	P. Anderson and N. Kedersha, “Rna Granules,” Journal of Cell Biology 172, no. 6 (2006): 803–808, https://doi.org/10.1083/jcb.200512082.

[76]	P. Anderson and N. Kedersha, “Stress Granules: The Tao of Rna Triage,” Trends in Biochemical Sciences 33, no. 3 (2008): 141–150, https://doi.org/10.1016/j.tibs.2007.12.003.

[77]	N. Kedersha and P. Anderson, “Mammalian Stress Granules and Processing Bodies,” Methods in Enzymology 431 (2007): 61–81.

[78]	R. Parker and U. Sheth, “P Bodies and the Control of Mrna Translation and Degradation,” Molecular Cell 25, no. 5 (2007): 635–646, https://doi.org/10.1016/j.molcel.2007.02.011.

[79]	A. Eulalio, I. Behm-Ansmant, and E. Izaurralde, “P Bodies: At the Crossroads of Post-Transcriptional Pathways,” Nature Reviews Molecular Cell Biology 8, no. 1 (2007): 9–22, https://doi.org/10.1038/nrm2080.

[80]	T. Ohn, N. Kedersha, T. Hickman, et al., “A Functional Rnai Screen Links O-Glcnac Modification of Ribosomal Proteins to Stress Granule and Processing Body Assembly,” Nature Cell Biology 10, no. 10 (2008): 1224–1231, https://doi.org/10.1038/ncb1783.

[81]	M. Malumbres and M. Barbacid, “Cell Cycle, Cdks and Cancer: A Changing Paradigm,” Nature Reviews Cancer 9, no. 3 (2009): 153–166, https://doi.org/10.1038/nrc2602.

[82]	C. Slawson, N. E. Zachara, K. Vosseller, et al., “Perturbations in O-Linked Beta-N-Acetylglucosamine Protein Modification Cause Severe Defects in Mitotic Progression and Cytokinesis,” Journal of Biological Chemistry 280, no. 38 (2005): 32944–32956, https://doi.org/10.1074/jbc.M503396200.

[83]	V. Dehennaut, T. Lefebvre, C. Sellier, et al., “O-Linked N-Acetylglucosaminyltransferase Inhibition Prevents G2/M Transition in Xenopus Laevis Oocytes,” Journal of Biological Chemistry 282, no. 17 (2007): 12527–12536, https://doi.org/10.1074/jbc.M700444200.

[84]	L. Masclef, V. Dehennaut, M. Mortuaire, et al., “Cyclin D1 Stability Is Partly Controlled by O-Glcnacylation,” Frontiers in Endocrinology 10 (2019): 106, https://doi.org/10.3389/fendo.2019.00106.

[85]	S. Olivier-Van Stichelen, V. Dehennaut, A. Buzy, et al., “O-Glcnacylation Stabilizes Beta-Catenin Through Direct Competition With Phosphorylation at Threonine 41,” Faseb Journal 28, no. 8 (2014): 3325–3338, https://doi.org/10.1096/fj.13-243535.

[86]	S. Olivier-Van Stichelen, L. Drougat, V. Dehennaut, et al., “Serum-Stimulated Cell Cycle Entry Promotes Ncogt Synthesis Required for Cyclin D Expression,” Oncogenesis 1, no. 12 (2012): e36, https://doi.org/10.1038/oncsis.2012.36.

[87]	C. W. Mitchell, I. Czajewski, and D. M. F. van Aalten, “Bioinformatic Prediction of Putative Conveyers of O-Glcnac Transferase Intellectual Disability,” Journal of Biological Chemistry 298, no. 9 (2022): 102276, https://doi.org/10.1016/j.jbc.2022.102276.

[88]	C. W. Mitchell, H. Yuan, M. Sonderstrup-Jensen, et al., “O-Glcnacylation of the Intellectual Disability Protein Ddx3X Exerts Proteostatic Cell Cycle Control,” Open Biology 15, no. 7 (2025): 250064, https://doi.org/10.1098/rsob.250064.

[89]	E. Julien and W. Herr, “Proteolytic Processing Is Necessary to Separate and Ensure Proper Cell Growth and Cytokinesis Functions of Hcf-1,” Embo Journal 22, no. 10 (2003): 2360–2369, https://doi.org/10.1093/emboj/cdg242.

[90]	C. M. Woo, P. J. Lund, A. C. Huang, et al., “Mapping and Quantification of over 2000 O-Linked Glycopeptides in Activated Human T Cells With Isotope-Targeted Glycoproteomics (Isotag),” Molecular & Cellular Proteomics 17, no. 4 (2018): 764–775, https://doi.org/10.1074/mcp.RA117.000261.

[91]	Z. Wang, N. D. Udeshi, C. Slawson, et al., “Extensive Crosstalk between O-Glcnacylation and Phosphorylation Regulates Cytokinesis,” Science Signaling 3, no. 104 (2010): ra2, https://doi.org/10.1126/scisignal.2000526.

[92]	V. Dehennaut, M. Slomianny, A. Page, et al., “Identification of Structural and Functional O-Linked N-Acetylglucosamine-Bearing Proteins in Xenopus Laevis Oocyte,” Molecular & Cellular Proteomics 7, no. 11 (2008): 2229–2245, https://doi.org/10.1074/mcp.M700494-MCP200.

[93]	C. Slawson and F. E. Duncan, “Sweet Action: The Dynamics of O-Glcnacylation during Meiosis in Mouse Oocytes,” Molecular Reproduction and Development 82, no. 12 (2015): 915, https://doi.org/10.1002/mrd.22577.

[94]	K. Sakabe and G. W. Hart, “O-Glcnac Transferase Regulates Mitotic Chromatin Dynamics,” Journal of Biological Chemistry 285, no. 45 (2010): 34460–34468, https://doi.org/10.1074/jbc.M110.158170.

[95]	E. P. Tan, S. Caro, A. Potnis, et al., “O-Linked N-Acetylglucosamine Cycling Regulates Mitotic Spindle Organization,” Journal of Biological Chemistry 288, no. 38 (2013): 27085–27099, https://doi.org/10.1074/jbc.M113.470187.

[96]	C. Slawson, T. Lakshmanan, S. Knapp, et al., “A Mitotic Glcnacylation/Phosphorylation Signaling Complex Alters the Posttranslational State of the Cytoskeletal Protein Vimentin,” Molecular Biology of the Cell 19, no. 10 (2008): 4130–4140, https://doi.org/10.1091/mbc.e07-11-1146.

[97]	D. Fisher, L. Krasinska, D. Coudreuse, et al., “Phosphorylation Network Dynamics in the Control of Cell Cycle Transitions,” Journal of Cell Science 125, no. Pt 20 (2012): 4703–4711, https://doi.org/10.1242/jcs.106351.

[98]	C. Lanza, E. P. Tan, Z. Zhang, et al., “Reduced O-Glcnacase Expression Promotes Mitotic Errors and Spindle Defects,” Cell Cycle 15, no. 10 (2016): 1363–1375, https://doi.org/10.1080/15384101.2016.1167297.

[99]	H. Ruan, X. Han, M. Li, et al., “O-Glcnac Transferase/Host Cell Factor C1 Complex Regulates Gluconeogenesis by Modulating Pgc-1Alpha Stability,” Cell Metabolism 16, no. 2 (2012): 226–237, https://doi.org/10.1016/j.cmet.2012.07.006.

[100]

D. Kim, D. Ryu, M. Koh, et al., “Orphan Nuclear Receptor Estrogen-Related Receptor Gamma (Errgamma) Is Key Regulator of Hepatic Gluconeogenesis,” Journal of Biological Chemistry 287, no. 26 (2012): 21628–21639, https://doi.org/10.1074/jbc.M111.315168.

[101]

J. Misra, D. Kim, Y. S. Jung, et al., “O-Glcnacylation of Orphan Nuclear Receptor Estrogen-Related Receptor Gamma Promotes Hepatic Gluconeogenesis,” Diabetes 65, no. 10 (2016): 2835–2848, https://doi.org/10.2337/db15-1523.

[102]

Y. Urasaki, G. Pizzorno, and T. T. Le, “Chronic Uridine Administration Induces Fatty Liver and Pre-Diabetic Conditions in Mice,” PLoS ONE 11, no. 1 (2016): e0146994, https://doi.org/10.1371/journal.pone.0146994.

[103]

R. Dentin, S. Hedrick, J. Xie, et al., “Hepatic Glucose Sensing via the Creb Coactivator Crtc2,” Science 319, no. 5868 (2008): 1402–1405, https://doi.org/10.1126/science.1151363.

[104]

M. P. Housley, J. T. Rodgers, N. D. Udeshi, et al., “O-Glcnac Regulates Foxo Activation in Response to Glucose,” Journal of Biological Chemistry 283, no. 24 (2008): 16283–16292, https://doi.org/10.1074/jbc.M802240200.

[105]

M. P. Housley, N. D. Udeshi, J. T. Rodgers, et al., “A Pgc-1Alpha-O-Glcnac Transferase Complex Regulates Foxo Transcription Factor Activity in Response to Glucose,” Journal of Biological Chemistry 284, no. 8 (2009): 5148–5157, https://doi.org/10.1074/jbc.M808890200.

[106]

M. Kuo, V. Zilberfarb, N. Gangneux, et al., “O-Glcnac Modification of Foxo1 Increases Its Transcriptional Activity: A Role in the Glucotoxicity Phenomenon?,” Biochimie 90, no. 5 (2008): 679–685, https://doi.org/10.1016/j.biochi.2008.03.005.

[107]

D. A. Babu, T. G. Deering, and R. G. Mirmira, “A Feat of Metabolic Proportions: Pdx1 Orchestrates Islet Development and Function in the Maintenance of Glucose Homeostasis,” Molecular Genetics and Metabolism 92, no. 1–2 (2007): 43–55, https://doi.org/10.1016/j.ymgme.2007.06.008.

[108]

Y. Gao, J. Miyazaki, and G. W. Hart, “The Transcription Factor Pdx-1 Is Post-Translationally Modified by O-Linked N-Acetylglucosamine and this Modification Is Correlated With Its Dna Binding Activity and Insulin Secretion in Min6 Beta-Cells,” Archives of Biochemistry and Biophysics 415, no. 2 (2003): 155–163, https://doi.org/10.1016/S0003-9861(03)00234-0.

[109]

J. H. Chae, G. H. Stein, and J. E. Lee, “Neurod: The Predicted and the Surprising,” Molecules and Cells 18, no. 3 (2004): 271–288, https://doi.org/10.1016/S1016-8478(23)13113-X.

[110]

H. V. Petersen, J. N. Jensen, R. Stein, et al., “Glucose Induced Mapk Signalling Influences Neurod1-Mediated Activation and Nuclear Localization,” Febs Letters 528, no. 1–3 (2002): 241–245, https://doi.org/10.1016/S0014-5793(02)03318-5.

[111]

S. S. Andrali, Q. Qian, and S. Ozcan, “Glucose Mediates the Translocation of Neurod1 by O-Linked Glycosylation,” Journal of Biological Chemistry 282, no. 21 (2007): 15589–15596, https://doi.org/10.1074/jbc.M701762200.

[112]

X. Cheng and L. B. Case, “Phase Separation in Chemical and Mechanical Signal Transduction,” Current Opinion in Cell Biology 85 (2023): 102243, https://doi.org/10.1016/j.ceb.2023.102243.

[113]

M. F. Ullo and L. B. Case, “How Cells Sense and Integrate Information from Different Sources,” Wires Mechanisms of Disease 15, no. 4 (2023): e1604, https://doi.org/10.1002/wsbm.1604.

[114]

D. Wootten, A. Christopoulos, M. Marti-Solano, et al., “Mechanisms of Signalling and Biased Agonism in G Protein-Coupled Receptors,” Nature Reviews Molecular Cell Biology 19, no. 10 (2018): 638–653, https://doi.org/10.1038/s41580-018-0049-3.

[115]

A. S. Hauser, M. M. Attwood, M. Rask-Andersen, et al., “Trends in Gpcr Drug Discovery: New Agents, Targets and Indications,” Nature Reviews Drug Discovery 16, no. 12 (2017): 829–842, https://doi.org/10.1038/nrd.2017.178.

[116]

C. Y. Logan and R. Nusse, “The Wnt Signaling Pathway in Development and Disease,” Annual Review of Cell and Developmental Biology 20 (2004): 781–810, https://doi.org/10.1146/annurev.cellbio.20.010403.113126.

[117]

Z. Steinhart and S. Angers, “Wnt Signaling in Development and Tissue Homeostasis,” Development (Cambridge, England) 145, no. 11 (2018), https://doi.org/10.1242/dev.146589.

[118]

[119]

M. Hart, J. P. Concordet, I. Lassot, et al., “The F-Box Protein Beta-Trcp Associates With Phosphorylated Beta-Catenin and Regulates Its Activity in the Cell,” Current Biology 9, no. 4 (1999): 207–210, https://doi.org/10.1016/S0960-9822(99)80091-8.

[120]

C. Liu, Y. Li, M. Semenov, et al., “Control of Beta-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism,” Cell 108, no. 6 (2002): 837–847, https://doi.org/10.1016/S0092-8674(02)00685-2.

[121]

Y. Zhu and G. W. Hart, “Dual-Specificity Rna Aptamers Enable Manipulation of Target-Specific O-Glcnacylation and Unveil Functions of O-Glcnac on Beta-Catenin,” Cell 186, no. 2 (2023): 428–445, https://doi.org/10.1016/j.cell.2022.12.016.

[122]

S. S. Olivier-Van, V. Dehennaut, A. Buzy, et al., “O-Glcnacylation Stabilizes Beta-Catenin Through Direct Competition With Phosphorylation at Threonine 41,” Faseb Journal 28, no. 8 (2014): 3325–3338.

[123]

V. S. Li, S. S. Ng, P. J. Boersema, et al., “Wnt Signaling Through Inhibition of Beta-Catenin Degradation in an Intact Axin1 Complex,” Cell 149, no. 6 (2012): 1245–1256, https://doi.org/10.1016/j.cell.2012.05.002.

[124]

Z. Du and C. M. Lovly, “Mechanisms of Receptor Tyrosine Kinase Activation in Cancer,” Molecular Cancer 17, no. 1 (2018): 58, https://doi.org/10.1186/s12943-018-0782-4.

[125]

Q. Hua, “Insulin: A Small Protein With a Long Journey,” Protein & Cell 1, no. 6 (2010): 537–551, https://doi.org/10.1007/s13238-010-0069-z.

[126]

X. Yang, P. P. Ongusaha, P. D. Miles, et al., “Phosphoinositide Signalling Links O-Glcnac Transferase to Insulin Resistance,” Nature 451, no. 7181 (2008): 964–969, https://doi.org/10.1038/nature06668.

[127]

G. Sabio and R. J. Davis, “Tnf and Map Kinase Signalling Pathways,” Seminars in Immunology 26, no. 3 (2014): 237–245, https://doi.org/10.1016/j.smim.2014.02.009.

[128]

Y. Keshet and R. Seger, “The Map Kinase Signaling Cascades: A System of Hundreds of Components Regulates a Diverse Array of Physiological Functions,” Methods in Molecular Biology 661 (2010): 3–38.

[129]

Z. M. Nelson, G. D. Leonard, and C. Fehl, “Tools for Investigating O-Glcnac in Signaling and Other Fundamental Biological Pathways,” Journal of Biological Chemistry 300, no. 2 (2024): 105615, https://doi.org/10.1016/j.jbc.2023.105615.

[130]

W. J. Leonard and J. X. Lin, “Cytokine Receptor Signaling Pathways,” Journal of Allergy and Clinical Immunology 105, no. 5 (2000): 877–888, https://doi.org/10.1067/mai.2000.106899.

[131]

A. Qiang, C. Slawson, and P. E. Fields, “The Role of O-Glcnacylation in Immune Cell Activation,” Frontiers in Endocrinology 12 (2021): 596617, https://doi.org/10.3389/fendo.2021.596617.

[132]

M. R. Zinatizadeh, B. Schock, G. M. Chalbatani, et al., “The Nuclear Factor Kappa B (Nf-Kb) Signaling in Cancer Development and Immune Diseases,” Genes & Diseases 8, no. 3 (2021): 287–297, https://doi.org/10.1016/j.gendis.2020.06.005.

[133]

W. H. Yang, S. Y. Park, H. W. Nam, et al., “Nfkappab Activation Is Associated With Its O-Glcnacylation State under Hyperglycemic Conditions,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 45 (2008): 17345–17350, https://doi.org/10.1073/pnas.0806198105.

[134]

S. Pathak, V. S. Borodkin, O. Albarbarawi, et al., “O-Glcnacylation of Tab1 Modulates Tak1-Mediated Cytokine Release,” Embo Journal 31, no. 6 (2012): 1394–1404, https://doi.org/10.1038/emboj.2012.8.

[135]

Q. Wang, P. Fang, R. He, et al., “O-Glcnac Transferase Promotes Influenza a Virus-Induced Cytokine Storm by Targeting Interferon Regulatory Factor-5,” Science Advances 6, no. 16 (2020): eaaz7086, https://doi.org/10.1126/sciadv.aaz7086.

[136]

Q. Zhu, H. Wang, S. Chai, et al., “O-Glcnacylation Promotes Tumor Immune Evasion by Inhibiting Pd-L1 Lysosomal Degradation,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 13 (2023): e2078171176.

[137]

J. Zhang, D. P. Ten, M. Wuhrer, et al., “Role of Glycosylation in Tgf-Beta Signaling and Epithelial-to-Mesenchymal Transition in Cancer,” Protein & Cell 12, no. 2 (2021): 89–106, https://doi.org/10.1007/s13238-020-00741-7.

[138]

R. N. Cole and G. W. Hart, “Cytosolic O-Glycosylation Is Abundant in Nerve Terminals,” Journal of Neurochemistry 79, no. 5 (2001): 1080–1089, https://doi.org/10.1046/j.1471-4159.2001.00655.x.

[139]

J. R. Erickson, L. Pereira, L. Wang, et al., “Diabetic Hyperglycaemia Activates Camkii and Arrhythmias by O-Linked Glycosylation,” Nature 502, no. 7471 (2013): 372–376, https://doi.org/10.1038/nature12537.

[140]

K. Vosseller, J. C. Trinidad, R. J. Chalkley, et al., “O-Linked N-Acetylglucosamine Proteomics of Postsynaptic Density Preparations Using Lectin Weak Affinity Chromatography and Mass Spectrometry,” Molecular & Cellular Proteomics 5, no. 5 (2006): 923–934, https://doi.org/10.1074/mcp.T500040-MCP200.

[141]

N. Khidekel, S. B. Ficarro, E. C. Peters, et al., “Exploring the O-Glcnac Proteome: Direct Identification of O-Glcnac-Modified Proteins from the Brain,” Proceedings of the National Academy of Sciences of the United States of America 101, no. 36 (2004): 13132–13137, https://doi.org/10.1073/pnas.0403471101.

[142]

E. W. Taylor, K. Wang, A. R. Nelson, et al., “O-Glcnacylation of Ampa Receptor Glua2 Is Associated With a Novel Form of Long-Term Depression at Hippocampal Synapses,” Journal of Neuroscience 34, no. 1 (2014): 10–21, https://doi.org/10.1523/JNEUROSCI.4761-12.2014.

[143]

W. B. Dias, W. D. Cheung, Z. Wang, et al., “Regulation of Calcium/Calmodulin-Dependent Kinase IV by O-Glcnac Modification,” Journal of Biological Chemistry 284, no. 32 (2009): 21327–21337, https://doi.org/10.1074/jbc.M109.007310.

[144]

J. E. Rexach, P. M. Clark, D. E. Mason, et al., “Dynamic O-Glcnac Modification Regulates Creb-Mediated Gene Expression and Memory Formation,” Nature Chemical Biology 8, no. 3 (2012): 253–261, https://doi.org/10.1038/nchembio.770.

[145]

Z. Breijyeh and R. Karaman, “Comprehensive Review on Alzheimer's Disease: Causes and Treatment,” Molecules (Basel, Switzerland) 25, no. 24 (2020), https://doi.org/10.3390/molecules25245789.

[146]

F. Liu, J. Shi, H. Tanimukai, et al., “Reduced O-Glcnacylation Links Lower Brain Glucose Metabolism and Tau Pathology in Alzheimer's Disease,” Brain 132, no. Pt 7 (2009): 1820–1832, https://doi.org/10.1093/brain/awp099.

[147]

A. T. Balana, P. M. Levine, T. W. Craven, et al., “O-Glcnac Modification of Small Heat Shock Proteins Enhances Their Anti-Amyloid Chaperone Activity,” Nature Chemistry 13, no. 5 (2021): 441–450, https://doi.org/10.1038/s41557-021-00648-8.

[148]

J. Park, H. J. Ha, E. S. Chung, et al., “O-Glcnacylation Ameliorates the Pathological Manifestations of Alzheimer's Disease by Inhibiting Necroptosis,” Science Advances 7, no. 3 (2021), https://doi.org/10.1126/sciadv.abd3207.

[149]

F. Liu, K. Iqbal, I. Grundke-Iqbal, et al., “O-Glcnacylation Regulates Phosphorylation of Tau: A Mechanism Involved in Alzheimer's Disease,” Proceedings of the National Academy of Sciences of the United States of America 101, no. 29 (2004): 10804–10809, https://doi.org/10.1073/pnas.0400348101.

[150]

C. S. Arnold, G. V. Johnson, R. N. Cole, et al., “The Microtubule-Associated Protein Tau Is Extensively Modified With O-Linked N-Acetylglucosamine,” Journal of Biological Chemistry 271, no. 46 (1996): 28741–28744, https://doi.org/10.1074/jbc.271.46.28741.

[151]

S. A. Yuzwa, A. K. Yadav, Y. Skorobogatko, et al., “Mapping O-Glcnac Modification Sites on Tau and Generation of a Site-Specific O-Glcnac Tau Antibody,” Amino Acids 40, no. 3 (2011): 857–868, https://doi.org/10.1007/s00726-010-0705-1.

[152]

K. Iqbal, A. C. Alonso, S. Chen, et al., “Tau Pathology in Alzheimer Disease and Other Tauopathies,” Biochimica Et Biophysica Acta 1739, no. 2–3 (2005): 198–210, https://doi.org/10.1016/j.bbadis.2004.09.008.

[153]

K. J. Kopeikina, B. T. Hyman, and T. L. Spires-Jones, “Soluble Forms of Tau Are Toxic in Alzheimer's Disease,” Translational Neuroscience 3, no. 3 (2012): 223–233, https://doi.org/10.2478/s13380-012-0032-y.

[154]

S. A. Yuzwa, M. S. Macauley, J. E. Heinonen, et al., “A Potent Mechanism-Inspired O-Glcnacase Inhibitor That Blocks Phosphorylation of Tau in Vivo,” Nature Chemical Biology 4, no. 8 (2008): 483–490, https://doi.org/10.1038/nchembio.96.

[155]

S. A. Yuzwa, X. Shan, M. S. Macauley, et al., “Increasing O-Glcnac Slows Neurodegeneration and Stabilizes Tau against Aggregation,” Nature Chemical Biology 8, no. 4 (2012): 393–399, https://doi.org/10.1038/nchembio.797.

[156]

S. Lammich, E. Kojro, R. Postina, et al., “Constitutive and Regulated Alpha-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by a Disintegrin Metalloprotease,” Proceedings of the National Academy of Sciences of the United States of America 96, no. 7 (1999): 3922–3927, https://doi.org/10.1073/pnas.96.7.3922.

[157]

R. Vassar, B. D. Bennett, S. Babu-Khan, et al., “Beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease Bace,” Science 286, no. 5440 (1999): 735–741, https://doi.org/10.1126/science.286.5440.735.

[158]

G. Evin, R. Cappai, Q. X. Li, et al., “Candidate Gamma-Secretases in the Generation of the Carboxyl Terminus of the Alzheimer's Disease Beta a4 Amyloid: Possible Involvement of Cathepsin D,” Biochemistry 34, no. 43 (1995): 14185–14192, https://doi.org/10.1021/bi00043a024.

[159]

B. De Strooper, P. Saftig, K. Craessaerts, et al., “Deficiency of Presenilin-1 Inhibits the Normal Cleavage of Amyloid Precursor Protein,” Nature 391, no. 6665 (1998): 387–390, https://doi.org/10.1038/34910.

[160]

M. A. Busche and B. T. Hyman, “Synergy between Amyloid-Beta and Tau in Alzheimer's Disease,” Nature Neuroscience 23, no. 10 (2020): 1183–1193, https://doi.org/10.1038/s41593-020-0687-6.

[161]

L. S. Griffith, M. Mathes, and B. Schmitz, “Beta-Amyloid Precursor Protein Is Modified With O-Linked N-Acetylglucosamine,” Journal of Neuroscience Research 41, no. 2 (1995): 270–278, https://doi.org/10.1002/jnr.490410214.

[162]

C. Kim, D. W. Nam, S. Y. Park, et al., “O-Linked Beta-N-Acetylglucosaminidase Inhibitor Attenuates Beta-Amyloid Plaque and Rescues Memory Impairment,” Neurobiology of Aging 34, no. 1 (2013): 275–285, https://doi.org/10.1016/j.neurobiolaging.2012.03.001.

[163]

S. Shah, S. F. Lee, K. Tabuchi, et al., “Nicastrin Functions as a Gamma-Secretase-Substrate Receptor,” Cell 122, no. 3 (2005): 435–447, https://doi.org/10.1016/j.cell.2005.05.022.

[164]

X. Dong, L. Shu, J. Zhang, et al., “Ogt-Mediated O-Glcnacylation Inhibits Astrocytes Activation Through Modulating Nf-Kappab Signaling Pathway,” Journal of Neuroinflammation 20, no. 1 (2023): 146, https://doi.org/10.1186/s12974-023-02824-8.

[165]

G. Bedse, F. Di Domenico, G. Serviddio, et al., “Aberrant Insulin Signaling in Alzheimer's Disease: Current Knowledge,” Frontiers in Neuroscience 9 (2015): 204, https://doi.org/10.3389/fnins.2015.00204.

[166]

M. Salkovic-Petrisic and S. Hoyer, “Central Insulin Resistance as a Trigger for Sporadic Alzheimer-Like Pathology: An Experimental Approach,” Journal of Neural Transmission Supplementum no. 72 (2007): 217–233.

[167]

A. L. Klein, M. N. Berkaw, M. G. Buse, et al., “O-Linked N-Acetylglucosamine Modification of Insulin Receptor Substrate-1 Occurs in Close Proximity to Multiple Sh2 Domain Binding Motifs,” Molecular & Cellular Proteomics 8, no. 12 (2009): 2733–2745, https://doi.org/10.1074/mcp.M900207-MCP200.

[168]

S. J. Dos, A. Vizuete, F. Hansen, et al., “Early and Persistent O-Glcnac Protein Modification in the Streptozotocin Model of Alzheimer's Disease,” Journal of Alzheimers Disease 61, no. 1 (2018): 237–249.

[169]

O. B. Tysnes and A. Storstein, “Epidemiology of Parkinson's Disease,” Journal of Neural Transmission 124, no. 8 (2017): 901–905, https://doi.org/10.1007/s00702-017-1686-y.

[170]

H. Braak, T. K. Del, U. Rub, et al., “Staging of Brain Pathology Related to Sporadic Parkinson's Disease,” Neurobiology of Aging 24, no. 2 (2003): 197–211, https://doi.org/10.1016/S0197-4580(02)00065-9.

[171]

B. E. Lee, H. Y. Kim, H. J. Kim, et al., “O-Glcnacylation Regulates Dopamine Neuron Function, Survival and Degeneration in Parkinson Disease,” Brain 143, no. 12 (2020): 3699–3716, https://doi.org/10.1093/brain/awaa320.

[172]

J. Zhang, X. Li, and J. D. Li, “The Roles of Post-Translational Modifications on Alpha-Synuclein in the Pathogenesis of Parkinson's Diseases,” Frontiers in Neuroscience 13 (2019): 381, https://doi.org/10.3389/fnins.2019.00381.

[173]

Z. Wang, N. D. Udeshi, M. O'Malley, et al., “Enrichment and Site Mapping of O-Linked N-Acetylglucosamine by a Combination of Chemical/Enzymatic Tagging, Photochemical Cleavage, and Electron Transfer Dissociation Mass Spectrometry,” Molecular & Cellular Proteomics 9, no. 1 (2010): 153–160, https://doi.org/10.1074/mcp.M900268-MCP200.

[174]

W. S. Kim, K. Kagedal, and G. M. Halliday, “Alpha-Synuclein Biology in Lewy Body Diseases,” Alzheimers Research & Therapy 6, no. 5 (2014): 73, https://doi.org/10.1186/s13195-014-0073-2.

[175]

I. C. Bras and T. F. Outeiro, “Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies,” Cells 10, no. 2 (2021), https://doi.org/10.3390/cells10020375.

[176]

N. P. Marotta, Y. H. Lin, Y. E. Lewis, et al., “O-Glcnac Modification Blocks the Aggregation and Toxicity of the Protein Alpha-Synuclein Associated With Parkinson's Disease,” Nature Chemistry 7, no. 11 (2015): 913–920, https://doi.org/10.1038/nchem.2361.

[177]

P. M. Levine, A. Galesic, A. T. Balana, et al., “Alpha-Synuclein O-Glcnacylation Alters Aggregation and Toxicity, Revealing Certain Residues as Potential Inhibitors of Parkinson's Disease,” Proceedings of the National Academy of Sciences of the United States of America 116, no. 5 (2019): 1511–1519, https://doi.org/10.1073/pnas.1808845116.

[178]

A. Galesic, A. Rakshit, G. Cutolo, et al., “Comparison of N-Acetyl-Glucosamine to Other Monosaccharides Reveals Structural Differences for the Inhibition of Alpha-Synuclein Aggregation,” Acs Chemical Biology 16, no. 1 (2021): 14–19, https://doi.org/10.1021/acschembio.0c00716.

[179]

B. E. Lee, P. G. Suh, and J. I. Kim, “O-Glcnacylation in Health and Neurodegenerative Diseases,” Experimental and Molecular Medicine 53, no. 11 (2021): 1674–1682, https://doi.org/10.1038/s12276-021-00709-5.

[180]

P. McColgan and S. J. Tabrizi, “Huntington's Disease: A Clinical Review,” European Journal of Neurology 25, no. 1 (2018): 24–34, https://doi.org/10.1111/ene.13413.

[181]

F. O. Walker, “Huntington's Disease,” Lancet 369, no. 9557 (2007): 218–228, https://doi.org/10.1016/S0140-6736(07)60111-1.

[182]

S. J. Tabrizi, M. D. Flower, C. A. Ross, et al., “Huntington Disease: New Insights into Molecular Pathogenesis and Therapeutic Opportunities,” Nature Reviews Neurology 16, no. 10 (2020): 529–546, https://doi.org/10.1038/s41582-020-0389-4.

[183]

L. W. Ho, R. Brown, M. Maxwell, et al., “Wild Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin in Mammalian Cell Models of Huntington's Disease,” Journal of Medical Genetics 38, no. 7 (2001): 450–452, https://doi.org/10.1136/jmg.38.7.450.

[184]

E. Wulff-Fuentes, R. R. Berendt, L. Massman, et al., “The Human O-Glcnacome Database and Meta-Analysis,” Scientific Data 8, no. 1 (2021): 25, https://doi.org/10.1038/s41597-021-00810-4.

[185]

A. Kumar, P. K. Singh, R. Parihar, et al., “Decreased O-Linked Glcnacylation Protects from Cytotoxicity Mediated by Huntingtin Exon1 Protein Fragment,” Journal of Biological Chemistry 289, no. 19 (2014): 13543–13553, https://doi.org/10.1074/jbc.M114.553321.

[186]

J. C. Grima, J. G. Daigle, N. Arbez, et al., “Mutant Huntingtin Disrupts the Nuclear Pore Complex,” Neuron 94, no. 1 (2017): 93–107, https://doi.org/10.1016/j.neuron.2017.03.023.

[187]

Y. Zhu, T. W. Liu, Z. Madden, et al., “Post-Translational O-Glcnacylation Is Essential for Nuclear Pore Integrity and Maintenance of the Pore Selectivity Filter,” Journal of Molecular Cell Biology 8, no. 1 (2016): 2–16, https://doi.org/10.1093/jmcb/mjv033.

[188]

S. A. Goutman, O. Hardiman, A. Al-Chalabi, et al., “Recent Advances in the Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis,” Lancet Neurology 21, no. 5 (2022): 480–493, https://doi.org/10.1016/S1474-4422(21)00465-8.

[189]

E. Beeldman, R. Govaarts, M. de Visser, et al., “Progression of Cognitive and Behavioural Impairment in Early Amyotrophic Lateral Sclerosis,” Journal of Neurology Neurosurgery and Psychiatry 91, no. 7 (2020): 779–780, https://doi.org/10.1136/jnnp-2020-322992.

[190]

N. Pender, M. Pinto-Grau, and O. Hardiman, “Cognitive and Behavioural Impairment in Amyotrophic Lateral Sclerosis,” Current Opinion in Neurology 33, no. 5 (2020): 649–654, https://doi.org/10.1097/WCO.0000000000000862.

[191]

C. Crockford, J. Newton, K. Lonergan, et al., “Als-Specific Cognitive and Behavior Changes Associated With Advancing Disease Stage in Als,” Neurology 91, no. 15 (2018): e1370–e1380, https://doi.org/10.1212/WNL.0000000000006317.

[192]

E. Bersano, M. F. Sarnelli, V. Solara, et al., “Decline of Cognitive and Behavioral Functions in Amyotrophic Lateral Sclerosis: A Longitudinal Study,” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21, no. 5–6 (2020): 373–379, https://doi.org/10.1080/21678421.2020.1771732.

[193]

M. Corbo and A. P. Hays, “Peripherin and Neurofilament Protein Coexist in Spinal Spheroids of Motor Neuron Disease,” Journal of Neuropathology and Experimental Neurology 51, no. 5 (1992): 531–537, https://doi.org/10.1097/00005072-199209000-00008.

[194]

D. L. Dong, Z. S. Xu, M. R. Chevrier, et al., “Glycosylation of Mammalian Neurofilaments. Localization of Multiple O-Linked N-Acetylglucosamine Moieties on Neurofilament Polypeptides L and M,” Journal of Biological Chemistry 268, no. 22 (1993): 16679–16687, https://doi.org/10.1016/S0021-9258(19)85471-6.

[195]

Y. Deng, B. Li, F. Liu, et al., “Regulation between O-Glcnacylation and Phosphorylation of Neurofilament-M and Their Dysregulation in Alzheimer Disease,” Faseb Journal 22, no. 1 (2008): 138–145, https://doi.org/10.1096/fj.07-8309com.

[196]

D. L. Dong, Z. S. Xu, G. W. Hart, et al., “Cytoplasmic O-Glcnac Modification of the Head Domain and the Ksp Repeat Motif of the Neurofilament Protein Neurofilament-H,” Journal of Biological Chemistry 271, no. 34 (1996): 20845–20852, https://doi.org/10.1074/jbc.271.34.20845.

[197]

S. Xiao, J. McLean, and J. Robertson, “Neuronal Intermediate Filaments and Als: A New Look at an Old Question,” Biochimica Et Biophysica Acta 1762, no. 11–12 (2006): 1001–1012, https://doi.org/10.1016/j.bbadis.2006.09.003.

[198]

C. S. Lobsiger, M. L. Garcia, C. M. Ward, et al., “Altered Axonal Architecture by Removal of the Heavily Phosphorylated Neurofilament Tail Domains Strongly Slows Superoxide Dismutase 1 Mutant-Mediated Als,” Proceedings of the National Academy of Sciences of the United States of America 102, no. 29 (2005): 10351–10356, https://doi.org/10.1073/pnas.0503862102.

[199]

N. Ludemann, A. Clement, V. H. Hans, et al., “O-Glycosylation of the Tail Domain of Neurofilament Protein M in Human Neurons and in Spinal Cord Tissue of a Rat Model of Amyotrophic Lateral Sclerosis (Als),” Journal of Biological Chemistry 280, no. 36 (2005): 31648–31658, https://doi.org/10.1074/jbc.M504395200.

[200]

T. J. Cohen, V. M. Lee, and J. Q. Trojanowski, “Tdp-43 Functions and Pathogenic Mechanisms Implicated in Tdp-43 Proteinopathies,” Trends in Molecular Medicine 17, no. 11 (2011): 659–667, https://doi.org/10.1016/j.molmed.2011.06.004.

[201]

S. Morgan and R. W. Orrell, “Pathogenesis of Amyotrophic Lateral Sclerosis,” British Medical Bulletin 119, no. 1 (2016): 87–98, https://doi.org/10.1093/bmb/ldw026.

[202]

S. Saberi, J. E. Stauffer, D. J. Schulte, et al., “Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants,” Neurologic Clinics 33, no. 4 (2015): 855–876, https://doi.org/10.1016/j.ncl.2015.07.012.

[203]

M. J. Zhao, X. Yao, P. Wei, et al., “O-Glcnacylation of Tdp-43 Suppresses Proteinopathies and Promotes Tdp-43'S Mrna Splicing Activity,” Embo Reports 22, no. 6 (2021): e51649, https://doi.org/10.15252/embr.202051649.

[204]

Y. L. Hsieh, F. Y. Su, L. K. Tsai, et al., “Npgpx-Mediated Adaptation to Oxidative Stress Protects Motor Neurons from Degeneration in Aging by Directly Modulating O-Glcnacase,” Cell Reports 29, no. 8 (2019): 2134–2143, https://doi.org/10.1016/j.celrep.2019.10.053.

[205]

A. A. Thai, B. J. Solomon, L. V. Sequist, et al., “Lung Cancer,” Lancet 398, no. 10299 (2021): 535–554, https://doi.org/10.1016/S0140-6736(21)00312-3.

[206]

Y. Y. Liu, H. Y. Liu, T. J. Yu, et al., “O-Glcnacylation of Morc2 at Threonine 556 by Ogt Couples Tgf-Beta Signaling to Breast Cancer Progression,” Cell Death and Differentiation 29, no. 4 (2022): 861–873, https://doi.org/10.1038/s41418-021-00901-0.

[207]

L. Lin, Q. Yuan, J. Gu, et al., “Carm1-Mediated Ogt Arginine Methylation Promotes Non-Small Cell Lung Cancer Glycolysis by Stabilizing Ogt,” Cell Death & Disease 15, no. 12 (2024): 927, https://doi.org/10.1038/s41419-024-07313-1.

[208]

S. Luanpitpong, N. Rodboon, P. Samart, et al., “A Novel Trpm7/O-Glcnac Axis Mediates Tumour Cell Motility and Metastasis by Stabilising C-Myc and Caveolin-1 in Lung Carcinoma,” British Journal of Cancer 123, no. 8 (2020): 1289–1301, https://doi.org/10.1038/s41416-020-0991-7.

[209]

C. H. Lin, C. C. Liao, S. Y. Wang, et al., “Comparative O-Glcnac Proteomic Analysis Reveals a Role of O-Glcnacylated Sam68 in Lung Cancer Aggressiveness,” Cancers 14, no. 1 (2022), https://doi.org/10.3390/cancers14010243.

[210]

X. Ge, X. Peng, M. Li, et al., “Ogt Regulated O-Glcnacylation Promotes Migration and Invasion by Activating Il-6/Stat3 Signaling in Nsclc Cells,” Pathology Research and Practice 225 (2021): 153580, https://doi.org/10.1016/j.prp.2021.153580.

[211]

T. Iwasaki, W. W. Chin, and L. Ko, “Identification and Characterization of Rrm-Containing Coactivator Activator (Coaa) as Trbp-Interacting Protein, and Its Splice Variant as a Coactivator Modulator (Coam),” Journal of Biological Chemistry 276, no. 36 (2001): 33375–33383, https://doi.org/10.1074/jbc.M101517200.

[212]

D. Auboeuf, D. H. Dowhan, X. Li, et al., “Coaa, a Nuclear Receptor Coactivator Protein at the Interface of Transcriptional Coactivation and Rna Splicing,” Molecular and Cellular Biology 24, no. 1 (2004): 442–453, https://doi.org/10.1128/MCB.24.1.442-453.2004.

[213]

T. H. Kweon, H. Jung, J. Y. Ko, et al., “O-Glcnacylation of Rbm14 Contributes to Elevated Cellular O-Glcnac Through Regulation of Oga Protein Stability,” Cell Reports 43, no. 5 (2024): 114163, https://doi.org/10.1016/j.celrep.2024.114163.

[214]

K. Itoh, N. Wakabayashi, Y. Katoh, et al., “Keap1 Represses Nuclear Activation of Antioxidant Responsive Elements by Nrf2 Through Binding to the Amino-Terminal Neh2 Domain,” Genes & Development 13, no. 1 (1999): 76–86, https://doi.org/10.1101/gad.13.1.76.

[215]

Y. Zhang, C. Sun, L. Ma, et al., “O-Glcnacylation Promotes Malignancy and Cisplatin Resistance of Lung Cancer by Stabilising Nrf2,” Clinical and Translational Medicine 14, no. 10 (2024): e70037, https://doi.org/10.1002/ctm2.70037.

[216]

S. Vomund, A. Schafer, M. J. Parnham, et al., “Nrf2, the Master Regulator of Anti-Oxidative Responses,” International Journal of Molecular Sciences 18, no. 12 (2017), https://doi.org/10.3390/ijms18122772.

[217]

[218]

[219]

J. Zhao, Z. Zhao, W. Zhou, et al., “Yeats2 O-Glcnacylation Promotes Chromatin Association of the Atac Complex and Lung Cancer Tumorigenesis,” Journal of Biological Chemistry 301, no. 7 (2025): 110388, https://doi.org/10.1016/j.jbc.2025.110388.

[220]

H. G. Khorana, J. F. Fernandes, and A. Kornberg, “Pyrophosphorylation of Ribose 5-Phosphate in the Enzymatic Synthesis of 5-Phosphorylribose 1-Pyrophosphate,” Journal of Biological Chemistry 230, no. 2 (1958): 941–948.

[221]

L. Chen, Q. Zhou, P. Zhang, et al., “Direct Stimulation of De Novo Nucleotide Synthesis by O-Glcnacylation,” Nature Chemical Biology 20, no. 1 (2024): 19–29, https://doi.org/10.1038/s41589-023-01354-x.

[222]

C. Alfaro, M. F. Sanmamed, M. E. Rodriguez-Ruiz, et al., “Interleukin-8 in Cancer Pathogenesis, Treatment and Follow-Up,” Cancer Treatment Reviews 60 (2017): 24–31, https://doi.org/10.1016/j.ctrv.2017.08.004.

[223]

J. M. David, C. Dominguez, D. H. Hamilton, et al., “The Il-8/Il-8R Axis: A Double Agent in Tumor Immune Resistance,” Vaccines 4, no. 3 (2016), https://doi.org/10.3390/vaccines4030022.

[224]

M. Shimizu and N. Tanaka, “Il-8-Induced O-Glcnac Modification via Glut3 and Gfat Regulates Cancer Stem Cell-Like Properties in Colon and Lung Cancer Cells,” Oncogene 38, no. 9 (2019): 1520–1533, https://doi.org/10.1038/s41388-018-0533-4.

[225]

[226]

Y. J. Kim, M. J. Kang, E. Kim, et al., “O-Glcnac Stabilizes Smad4 by Inhibiting Gsk-3Beta-Mediated Proteasomal Degradation,” Scientific Reports 10, no. 1 (2020): 19908, https://doi.org/10.1038/s41598-020-76862-0.

[227]

[228]

L. A. Torre, F. Bray, R. L. Siegel, et al., “Global Cancer Statistics,” Ca-a Cancer Journal for Clinicians 65, no. 2 (2012): 87–108.

[229]

H. B. El-Serag, “Hepatocellular Carcinoma,” New England Journal of Medicine 365, no. 12 (2011): 1118–1127, https://doi.org/10.1056/NEJMra1001683.

[230]

W. Xu, X. Zhang, J. L. Wu, et al., “O-Glcnac Transferase Promotes Fatty Liver-Associated Liver Cancer Through Inducing Palmitic Acid and Activating Endoplasmic Reticulum Stress,” Journal of Hepatology 67, no. 2 (2017): 310–320, https://doi.org/10.1016/j.jhep.2017.03.017.

[231]

H. Nakagawa, A. Umemura, K. Taniguchi, et al., “Er Stress Cooperates With Hypernutrition to Trigger Tnf-Dependent Spontaneous Hcc Development,” Cancer Cell 26, no. 3 (2014): 331–343, https://doi.org/10.1016/j.ccr.2014.07.001.

[232]

C. Garcia-Ruiz, J. M. Mato, D. Vance, et al., “Acid Sphingomyelinase-Ceramide System in Steatohepatitis: A Novel Target Regulating Multiple Pathways,” Journal of Hepatology 62, no. 1 (2015): 219–233, https://doi.org/10.1016/j.jhep.2014.09.023.

[233]

S. Raab, A. Gadault, N. Very, et al., “Dual Regulation of Fatty Acid Synthase (Fasn) Expression by O-Glcnac Transferase (Ogt) and Mtor Pathway in Proliferating Liver Cancer Cells,” Cellular and Molecular Life Sciences 78, no. 13 (2021): 5397–5413, https://doi.org/10.1007/s00018-021-03857-z.

[234]

D. Matallanas, M. Birtwistle, D. Romano, et al., “Raf Family Kinases: Old Dogs Have Learned New Tricks,” Genes & Cancer 2, no. 3 (2011): 232–260, https://doi.org/10.1177/1947601911407323.

[235]

D. Ning, J. Chen, P. Du, et al., “The Crosstalk Network of Xist/Mir-424-5P/Ogt Mediates Raf1 Glycosylation and Participates in the Progression of Liver Cancer,” Liver International 41, no. 8 (2021): 1933–1944, https://doi.org/10.1111/liv.14904.

[236]

J. Wang, L. Ma, W. Weng, et al., “Mutual Interaction between Yap and Creb Promotes Tumorigenesis in Liver Cancer,” Hepatology 58, no. 3 (2013): 1011–1020, https://doi.org/10.1002/hep.26420.

[237]

A. Perra, M. A. Kowalik, E. Ghiso, et al., “Yap Activation Is an Early Event and a Potential Therapeutic Target in Liver Cancer Development,” Journal of Hepatology 61, no. 5 (2014): 1088–1096, https://doi.org/10.1016/j.jhep.2014.06.033.

[238]

T. Y. Ryu, J. Park, and P. E. Scherer, “Hyperglycemia as a Risk Factor for Cancer Progression,” Diabetes & Metabolism Journal 38, no. 5 (2014): 330–336, https://doi.org/10.4093/dmj.2014.38.5.330.

[239]

X. Zhang, Y. Qiao, Q. Wu, et al., “The Essential Role of Yap O-Glcnacylation in High-Glucose-Stimulated Liver Tumorigenesis,” Nature Communications 8 (2017): 15280, https://doi.org/10.1038/ncomms15280.

[240]

E. Dekker, P. J. Tanis, J. Vleugels, et al., “Colorectal Cancer,” Lancet 394, no. 10207 (2019): 1467–1480, https://doi.org/10.1016/S0140-6736(19)32319-0.

[241]

A. Steenackers, S. S. Olivier-Van, S. F. Baldini, et al., “Silencing the Nucleocytoplasmic O-Glcnac Transferase Reduces Proliferation, Adhesion, and Migration of Cancer and Fetal Human Colon Cell Lines,” Frontiers in Endocrinology 7 (2016): 46, https://doi.org/10.3389/fendo.2016.00046.

[242]

T. Phueaouan, P. Chaiyawat, P. Netsirisawan, et al., “Aberrant O-Glcnac-Modified Proteins Expressed in Primary Colorectal Cancer,” Oncology Reports 30, no. 6 (2013): 2929–2936, https://doi.org/10.3892/or.2013.2794.

[243]

M. H. Kristensen, M. Weidinger, M. Bzorek, et al., “Correlation between Thymidylate Synthase Gene Variants, Rna and Protein Levels in Primary Colorectal Adenocarcinomas,” Journal of International Medical Research 38, no. 2 (2010): 484–497, https://doi.org/10.1177/147323001003800212.

[244]

Z. Chen, S. Han, W. Huang, et al., “Microrna-215 Suppresses Cell Proliferation, Migration and Invasion of Colon Cancer by Repressing Yin-Yang 1,” Biochemical and Biophysical Research Communications 479, no. 3 (2016): 482–488, https://doi.org/10.1016/j.bbrc.2016.09.089.

[245]

G. Zhu, M. Qian, L. Lu, et al., “O-Glcnacylation of Yy1 Stimulates Tumorigenesis in Colorectal Cancer Cells by Targeting Slc22a15 and Aanat,” Carcinogenesis 40, no. 9 (2019): 1121–1131.

[246]

J. Li, M. Ahmad, L. Sang, et al., “O-Glcnacylation Promotes the Cytosolic Localization of the M(6)a Reader Ythdf1 and Colorectal Cancer Tumorigenesis,” Journal of Biological Chemistry 299, no. 6 (2023): 104738, https://doi.org/10.1016/j.jbc.2023.104738.

[247]

H. Shi, J. Wei, and C. He, “Where, When, and How: Context-Dependent Functions of Rna Methylation Writers, Readers, and Erasers,” Molecular Cell 74, no. 4 (2019): 640–650, https://doi.org/10.1016/j.molcel.2019.04.025.

[248]

X. Wang, B. S. Zhao, I. A. Roundtree, et al., “N(6)-Methyladenosine Modulates Messenger Rna Translation Efficiency,” Cell 161, no. 6 (2015): 1388–1399, https://doi.org/10.1016/j.cell.2015.05.014.

[249]

Z. Yu, H. He, B. Jiang, et al., “O-Glcnacylation of Csnk2a1 by Ogt Is Involved in the Progression of Colorectal Cancer,” Molecular Biotechnology 67, no. 1 (2025): 272–283, https://doi.org/10.1007/s12033-024-01049-1.

[250]

X. Zhong, X. He, Y. Wang, et al., “Warburg Effect in Colorectal Cancer: The Emerging Roles in Tumor Microenvironment and Therapeutic Implications,” Journal of Hematology & Oncology 15, no. 1 (2022): 160, https://doi.org/10.1186/s13045-022-01358-5.

[251]

N. N. Pavlova and C. B. Thompson, “The Emerging Hallmarks of Cancer Metabolism,” Cell Metabolism 23, no. 1 (2016): 27–47, https://doi.org/10.1016/j.cmet.2015.12.006.

[252]

H. Wang, J. Sun, H. Sun, et al., “The Ogt-C-Myc-Pdk2 Axis Rewires the Tca Cycle and Promotes Colorectal Tumor Growth,” Cell Death and Differentiation 31, no. 9 (2024): 1157–1169, https://doi.org/10.1038/s41418-024-01315-4.

[253]

X. Luo, C. Cheng, Z. Tan, et al., “Emerging Roles of Lipid Metabolism in Cancer Metastasis,” Molecular Cancer 16, no. 1 (2017): 76, https://doi.org/10.1186/s12943-017-0646-3.

[254]

J. Drury, M. E. Geisen, J. W. Tessmann, et al., “Overexpression of Fatty Acid Synthase Upregulates Glutamine-Fructose-6-Phosphate Transaminase 1 and O-Linked N-Acetylglucosamine Transferase to Increase O-Glcnac Protein Glycosylation and Promote Colorectal Cancer Growth,” International Journal of Molecular Sciences 25, no. 9 (2024), https://doi.org/10.3390/ijms25094883.

[255]

C. A. Murillo, P. G. Rychahou, and B. M. Evers, “Inhibition of Alpha5 Integrin Decreases Pi3K Activation and Cell Adhesion of Human Colon Cancers,” Surgery 136, no. 2 (2004): 143–149, https://doi.org/10.1016/j.surg.2004.04.006.

[256]

C. Pelillo, A. Bergamo, H. Mollica, et al., “Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through Alpha5Beta1 Integrin,” Journal of Cellular Biochemistry 116, no. 10 (2015): 2385–2396, https://doi.org/10.1002/jcb.25189.

[257]

E. H. Nam, Y. Lee, X. F. Zhao, et al., “Zeb2-Sp1 Cooperation Induces Invasion by Upregulating Cadherin-11 and Integrin Alpha5 Expression,” Carcinogenesis 35, no. 2 (2014): 302–314, https://doi.org/10.1093/carcin/bgt340.

[258]

E. H. Nam, Y. Lee, B. Moon, et al., “Twist1 and Ap-1 Cooperatively Upregulate Integrin Alpha5 Expression to Induce Invasion and the Epithelial-Mesenchymal Transition,” Carcinogenesis 36, no. 3 (2015): 327–337, https://doi.org/10.1093/carcin/bgv005.

[259]

M. Yu, S. Chu, B. Fei, et al., “O-Glcnacylation of Itga5 Facilitates the Occurrence and Development of Colorectal Cancer,” Experimental Cell Research 382, no. 2 (2019): 111464, https://doi.org/10.1016/j.yexcr.2019.06.009.

[260]

M. Jiang, B. Xu, X. Li, et al., “O-Glcnacylation Promotes Colorectal Cancer Metastasis via the Mir-101-O-Glcnac/Ezh2 Regulatory Feedback Circuit,” Oncogene 38, no. 3 (2019): 301–316, https://doi.org/10.1038/s41388-018-0435-5.

[261]

M. Wang, L. Qiao, L. Jin, et al., “Ogt-Regulated O-Glcnacylation Promotes the Malignancy of Colorectal Cancer by Activating Stat2 to Induce Macrophage M2: Ogt Protein Macromolecule Action,” International Journal of Biological Macromolecules 311, no. Pt 3 (2025): 144057, https://doi.org/10.1016/j.ijbiomac.2025.144057.

[262]

H. I. Cho, S. Jo, M. S. Kim, et al., “Setd5 Regulates the Ogt-Catalyzed O-Glcnacylation of Rna Polymerase II, Which Is Involved in the Stemness of Colorectal Cancer Cells,” Scientific Reports 13, no. 1 (2023): 19885, https://doi.org/10.1038/s41598-023-46923-1.

[263]

[264]

V. L. Sodi, S. Khaku, R. Krutilina, et al., “Mtor/Myc Axis Regulates O-Glcnac Transferase Expression and O-Glcnacylation in Breast Cancer,” Molecular Cancer Research 13, no. 5 (2015): 923–933, https://doi.org/10.1158/1541-7786.MCR-14-0536.

[265]

Y. Uno and K. Hayakawa, “O-Glcnacylation on Serine 40 of Histone H2a Promotes Proliferation and Invasion in Triple-Negative Breast Cancer,” Scientific Reports 15, no. 1 (2025): 10170, https://doi.org/10.1038/s41598-025-95394-z.

[266]

C. M. Ferrer, T. Y. Lu, Z. A. Bacigalupa, et al., “O-Glcnacylation Regulates Breast Cancer Metastasis via Sirt1 Modulation of Foxm1 Pathway,” Oncogene 36, no. 4 (2017): 559–569, https://doi.org/10.1038/onc.2016.228.

[267]

C. Y. Koo, K. W. Muir, and E. W. Lam, “Foxm1: From Cancer Initiation to Progression and Treatment,” Biochimica Et Biophysica Acta 1819, no. 1 (2012): 28–37, https://doi.org/10.1016/j.bbagrm.2011.09.004.

[268]

Y. Gu, W. Mi, Y. Ge, et al., “Glcnacylation Plays an Essential Role in Breast Cancer Metastasis,” Cancer Research 70, no. 15 (2010): 6344–6351, https://doi.org/10.1158/0008-5472.CAN-09-1887.

[269]

M. Ghosh, X. Song, G. Mouneimne, et al., “Cofilin Promotes Actin Polymerization and Defines the Direction of Cell Motility,” Science 304, no. 5671 (2004): 743–746, https://doi.org/10.1126/science.1094561.

[270]

M. Sidani, D. Wessels, G. Mouneimne, et al., “Cofilin Determines the Migration Behavior and Turning Frequency of Metastatic Cancer Cells,” Journal of Cell Biology 179, no. 4 (2007): 777–791, https://doi.org/10.1083/jcb.200707009.

[271]

X. Huang, Q. Pan, D. Sun, et al., “O-Glcnacylation of Cofilin Promotes Breast Cancer Cell Invasion,” Journal of Biological Chemistry 288, no. 51 (2013): 36418–36425, https://doi.org/10.1074/jbc.M113.495713.

[272]

Y. Xu, X. Sheng, T. Zhao, et al., “O-Glcnacylation of Mek2 Promotes the Proliferation and Migration of Breast Cancer Cells,” Glycobiology 31, no. 5 (2021): 571–581, https://doi.org/10.1093/glycob/cwaa103.

[273]

N. Schmolka, I. D. Karemaker, D. S. R. Cardoso, et al., “Dissecting the Roles of Mbd2 Isoforms and Domains in Regulating Nurd Complex Function during Cellular Differentiation,” Nature Communications 14, no. 1 (2023): 3848, https://doi.org/10.1038/s41467-023-39551-w.

[274]

B. Wang, C. Li, J. Ming, et al., “The Nurd Complex Cooperates With Sall4 to Orchestrate Reprogramming,” Nature Communications 14, no. 1 (2023): 2846, https://doi.org/10.1038/s41467-023-38543-0.

[275]

C. L. Grzeskowiak, S. T. Kundu, X. Mo, et al., “In Vivo Screening Identifies Gatad2B as a Metastasis Driver in Kras-Driven Lung Cancer,” Nature Communications 9, no. 1 (2018): 2732, https://doi.org/10.1038/s41467-018-04572-3.

[276]

G. Le Minh, J. Merzy, E. M. Esquea, et al., “Gatad2B O-Glcnacylation Regulates Breast Cancer Stem-Like Potential and Drug Resistance,” Cells 14, no. 6 (2025), https://doi.org/10.3390/cells14060398.

[277]

N. M. Akella, G. Le Minh, L. Ciraku, et al., “O-Glcnac Transferase Regulates Cancer Stem-Like Potential of Breast Cancer Cells,” Molecular Cancer Research 18, no. 4 (2020): 585–598, https://doi.org/10.1158/1541-7786.MCR-19-0732.

[278]

G. Le Minh, E. M. Esquea, T. T. Dhameliya, et al., “Kruppel-Like Factor 8 Regulates Triple Negative Breast Cancer Stem Cell-Like Activity,” Frontiers in Oncology 13 (2023): 1141834, https://doi.org/10.3389/fonc.2023.1141834.

[279]

X. Li, Z. Wu, J. He, et al., “Ogt Regulated O-Glcnacylation Promotes Papillary Thyroid Cancer Malignancy via Activating Yap,” Oncogene 40, no. 30 (2021): 4859–4871, https://doi.org/10.1038/s41388-021-01901-7.

[280]

P. Zhang, C. Wang, T. Ma, et al., “O-Glcnacylation Enhances the Invasion of Thyroid Anaplastic Cancer Cells Partially by Pi3K/Akt1 Pathway,” Oncotargets and Therapy 8 (2015): 3305–3313.

[281]

Y. U. Cheng, H. Li, J. Li, et al., “O-Glcnacylation Enhances Anaplastic Thyroid Carcinoma Malignancy,” Oncology Letters 12, no. 1 (2016): 572–578, https://doi.org/10.3892/ol.2016.4647.

[282]

P. Zhang, Z. Luo, Y. Xu, et al., “Hypoxia-Induced Circprelid2 Promotes Gastric Cancer Metastasis by Facilitating Zeb2 Translation via Pcbp1 O-Glcnacylation,” Advanced Science (2025): e05396, https://doi.org/10.1002/advs.202505396.

[283]

M. Jiang, N. Wu, B. Xu, et al., “Fatty Acid-Induced Cd36 Expression via O-Glcnacylation Drives Gastric Cancer Metastasis,” Theranostics 9, no. 18 (2019): 5359–5373, https://doi.org/10.7150/thno.34024.

[284]

G. Wang, Z. Xu, J. Sun, et al., “O-Glcnacylation Enhances Reticulon 2 Protein Stability and Its Promotive Effects on Gastric Cancer Progression,” Cellular Signalling 108 (2023): 110718, https://doi.org/10.1016/j.cellsig.2023.110718.

[285]

Z. Qiao, C. Dang, B. Zhou, et al., “Downregulation of O-Linked N-Acetylglucosamine Transferase by Rna Interference Decreases Mmp9 Expression in Human Esophageal Cancer Cells,” Oncology Letters 11, no. 5 (2016): 3317–3323, https://doi.org/10.3892/ol.2016.4428.

[286]

H. Wu, S. Song, A. Yan, et al., “Rack1 Promotes the Invasive Activities and Lymph Node Metastasis of Cervical Cancer via Galectin-1,” Cancer Letters 469 (2020): 287–300, https://doi.org/10.1016/j.canlet.2019.11.002.

[287]

Q. Zeng, R. X. Zhao, J. Chen, et al., “O-Linked Glcnacylation Elevated by Hpv E6 Mediates Viral Oncogenesis,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 33 (2016): 9333–9338, https://doi.org/10.1073/pnas.1606801113.

[288]

C. Zhang, H. Jiang, L. Yuan, et al., “Circvprbp Inhibits Nodal Metastasis of Cervical Cancer by Impeding Rack1 O-Glcnacylation and Stability,” Oncogene 42, no. 11 (2023): 793–807, https://doi.org/10.1038/s41388-023-02595-9.

[289]

C. Zhang, H. Jiang, L. Yuan, et al., “Correction: Circvprbp Inhibits Nodal Metastasis of Cervical Cancer by Impeding Rack1 O-Glcnacylation and Stability,” Oncogene 44, no. 23 (2025): 1887–1890, https://doi.org/10.1038/s41388-025-03440-x.

[290]

A. Ali, S. H. Kim, M. J. Kim, et al., “O-Glcnacylation of Nf-Kappab Promotes Lung Metastasis of Cervical Cancer Cells via Upregulation of Cxcr4 Expression,” Molecules and Cells 40, no. 7 (2017): 476–484, https://doi.org/10.14348/molcells.2017.2309.

[291]

T. Yan, X. Ma, K. Zhou, et al., “A Novel Csn5/Crt O-Glcnac/Er Stress Regulatory Axis in Platinum Resistance of Epithelial Ovarian Cancer,” International Journal of Biological Sciences 20, no. 4 (2024): 1279–1296, https://doi.org/10.7150/ijbs.89700.

[292]

L. Qian, X. Yang, S. Li, et al., “Reduced O-Glcnacylation of Snap-23 Promotes Cisplatin Resistance by Inducing Exosome Secretion in Ovarian Cancer,” Cell Death Discovery 7, no. 1 (2021): 112, https://doi.org/10.1038/s41420-021-00489-x.

[293]

A. Rogalska, E. Forma, M. Brys, et al., “Hyperglycemia-Associated Dysregulation of O-Glcnacylation and Hif1a Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (Skov-3),” International Journal of Molecular Sciences 19, no. 9 (2018), https://doi.org/10.3390/ijms19092750.

[294]

J. Peng, J. Liu, M. Ning, et al., “Fluzoparib Disrupts Golgi Apparatus to Inhibit O-Glcnacylation and Nuclear Translocation of Beta-Catenin to Attenuate Ovarian Cancer Invasion and Metastasis,” International Immunopharmacology 162 (2025): 115158, https://doi.org/10.1016/j.intimp.2025.115158.

[295]

L. Xia, J. Mei, M. Huang, et al., “O-Glcnacylation in Ovarian Tumorigenesis and Its Therapeutic Implications,” Translational Oncology 51 (2025): 102220, https://doi.org/10.1016/j.tranon.2024.102220.

[296]

Z. Yan, Y. Li, M. Wang, et al., “O-Glcnacylation of Dj-1 Suppresses Ferroptosis in Renal Cell Carcinoma by Affecting the Transsulfuration Pathway,” International Immunopharmacology 148 (2025): 114098, https://doi.org/10.1016/j.intimp.2025.114098.

[297]

L. Wang, S. Chen, J. Zhang, et al., “Suppressed Ogt Expression Inhibits Cell Proliferation and Modulates Egfr Expression in Renal Cell Carcinoma,” Cancer Management and Research 11 (2019): 2215–2223, https://doi.org/10.2147/CMAR.S190642.

[298]

L. E. Olvera, B. D. Ballard, and A. Jan, “Cardiovascular Disease,” (2025).

[299]

G. D. Flora and M. K. Nayak, “A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes,” Current Pharmaceutical Design 25, no. 38 (2019): 4063–4084, https://doi.org/10.2174/1381612825666190925163827.

[300]

N. Townsend, D. Kazakiewicz, W. F. Lucy, et al., “Epidemiology of Cardiovascular Disease in Europe,” Nature Reviews Cardiology 19, no. 2 (2022): 133–143, https://doi.org/10.1038/s41569-021-00607-3.

[301]

H. F. Wang, Y. X. Wang, Y. P. Zhou, et al., “Protein O-Glcnacylation in Cardiovascular Diseases,” Acta Pharmacologica Sinica 44, no. 1 (2023): 8–18, https://doi.org/10.1038/s41401-022-00934-2.

[302]

J. N. Wright, H. E. Collins, A. R. Wende, et al., “O-Glcnacylation and Cardiovascular Disease,” Biochemical Society Transactions 45, no. 2 (2017): 545–553, https://doi.org/10.1042/BST20160164.

[303]

P. Umapathi, O. O. Mesubi, P. S. Banerjee, et al., “Excessive O-Glcnacylation Causes Heart Failure and Sudden Death,” Circulation 143, no. 17 (2021): 1687–1703, https://doi.org/10.1161/CIRCULATIONAHA.120.051911.

[304]

M. Ferron, M. Denis, A. Persello, et al., “Protein O-Glcnacylation in Cardiac Pathologies: Past, Present, Future,” Frontiers in Endocrinology 9 (2018): 819, https://doi.org/10.3389/fendo.2018.00819.

[305]

I. G. Lunde, J. M. Aronsen, H. Kvaloy, et al., “Cardiac O-Glcnac Signaling Is Increased in Hypertrophy and Heart Failure,” Physiological Genomics 44, no. 2 (2012): 162–172, https://doi.org/10.1152/physiolgenomics.00016.2011.

[306]

T. Y. Chou, G. W. Hart, and C. V. Dang, “C-Myc Is Glycosylated at Threonine 58, a Known Phosphorylation Site and a Mutational Hot Spot in Lymphomas,” Journal of Biological Chemistry 270, no. 32 (1995): 18961–18965, https://doi.org/10.1074/jbc.270.32.18961.

[307]

W. Zhong, S. Mao, S. Tobis, et al., “Hypertrophic Growth in Cardiac Myocytes Is Mediated by Myc Through a Cyclin D2-Dependent Pathway,” Embo Journal 25, no. 16 (2006): 3869–3879, https://doi.org/10.1038/sj.emboj.7601252.

[308]

G. A. Ramirez-Correa, W. Jin, Z. Wang, et al., “O-Linked Glcnac Modification of Cardiac Myofilament Proteins: A Novel Regulator of Myocardial Contractile Function,” Circulation Research 103, no. 12 (2008): 1354–1358, https://doi.org/10.1161/CIRCRESAHA.108.184978.

[309]

E. Dubois-Deruy, A. Belliard, P. Mulder, et al., “Interplay between Troponin T Phosphorylation and O-N-Acetylglucosaminylation in Ischaemic Heart Failure,” Cardiovascular Research 107, no. 1 (2015): 56–65, https://doi.org/10.1093/cvr/cvv136.

[310]

J. L. Jewell and K. L. Guan, “Nutrient Signaling to Mtor and Cell Growth,” Trends in Biochemical Sciences 38, no. 5 (2013): 233–242, https://doi.org/10.1016/j.tibs.2013.01.004.

[311]

S. Sciarretta, M. Volpe, and J. Sadoshima, “Mammalian Target of Rapamycin Signaling in Cardiac Physiology and Disease,” Circulation Research 114, no. 3 (2014): 549–564, https://doi.org/10.1161/CIRCRESAHA.114.302022.

[312]

D. H. Tran, H. I. May, Q. Li, et al., “Chronic Activation of Hexosamine Biosynthesis in the Heart Triggers Pathological Cardiac Remodeling,” Nature Communications 11, no. 1 (2020): 1771, https://doi.org/10.1038/s41467-020-15640-y.

[313]

S. Xie, N. Jin, J. Gu, et al., “O-Glcnacylation of Protein Kinase a Catalytic Subunits Enhances Its Activity: A Mechanism Linked to Learning and Memory Deficits in Alzheimer's Disease,” Aging Cell 15, no. 3 (2016): 455–464, https://doi.org/10.1111/acel.12449.

[314]

X. Chen, L. Zhang, H. He, et al., “Increased O-Glcnacylation Induces Myocardial Hypertrophy,” In Vitro Cellular & Developmental Biology-Animal 56, no. 9 (2020): 735–743, https://doi.org/10.1007/s11626-020-00503-z.

[315]

W. Yu, S. Hu, X. Xu, et al., “Association between O-Glcnac Transferase Activity and Major Adverse Cardiovascular Events: Findings from the China Peace-Mpp Cohort,” Bmc Cardiovascular Disorders 25, no. 1 (2025): 281, https://doi.org/10.1186/s12872-025-04732-6.

[316]

L. J. Watson, H. T. Facundo, G. A. Ngoh, et al., “O-Linked Beta-N-Acetylglucosamine Transferase Is Indispensable in the Failing Heart,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 41 (2010): 17797–17802, https://doi.org/10.1073/pnas.1001907107.

[317]

E. L. Krawitt, “Autoimmune Hepatitis,” New England Journal of Medicine 354, no. 1 (2006): 54–66, https://doi.org/10.1056/NEJMra050408.

[318]

R. Taubert, M. Hardtke-Wolenski, F. Noyan, et al., “Intrahepatic Regulatory T Cells in Autoimmune Hepatitis Are Associated With Treatment Response and Depleted With Current Therapies,” Journal of Hepatology 61, no. 5 (2014): 1106–1114, https://doi.org/10.1016/j.jhep.2014.05.034.

[319]

X. Hao, Y. Li, J. Wang, et al., “Deficient O-Glcnac Glycosylation Impairs Regulatory T Cell Differentiation and Notch Signaling in Autoimmune Hepatitis,” Frontiers in Immunology 9 (2018): 2089, https://doi.org/10.3389/fimmu.2018.02089.

[320]

T. Korn, E. Bettelli, M. Oukka, et al., “Il-17 and Th17 Cells,” Annual Review of Immunology 27 (2009): 485–517, https://doi.org/10.1146/annurev.immunol.021908.132710.

[321]

C. Dong, “Th17 Cells in Development: An Updated View of Their Molecular Identity and Genetic Programming,” Nature Reviews Immunology 8, no. 5 (2008): 337–348, https://doi.org/10.1038/nri2295.

[322]

I. I. Ivanov, B. S. McKenzie, L. Zhou, et al., “The Orphan Nuclear Receptor Rorgammat Directs the Differentiation Program of Proinflammatory Il-17+ T Helper Cells,” Cell 126, no. 6 (2006): 1121–1133, https://doi.org/10.1016/j.cell.2006.07.035.

[323]

X. O. Yang, B. P. Pappu, R. Nurieva, et al., “T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors Ror Alpha and Ror Gamma,” Immunity 28, no. 1 (2008): 29–39, https://doi.org/10.1016/j.immuni.2007.11.016.

[324]

R. Liu, X. Ma, L. Chen, et al., “Microrna-15B Suppresses Th17 Differentiation and Is Associated With Pathogenesis of Multiple Sclerosis by Targeting O-Glcnac Transferase,” Journal of Immunology 198, no. 7 (2017): 2626–2639, https://doi.org/10.4049/jimmunol.1601727.

[325]

J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid Arthritis,” Lancet 388, no. 10055 (2016): 2023–2038, https://doi.org/10.1016/S0140-6736(16)30173-8.

[326]

X. Yan, J. Zheng, W. Ren, et al., “O-Glcnacylation: Roles and Potential Therapeutic Target for Bone Pathophysiology,” Cell Communication and Signaling 22, no. 1 (2024): 279, https://doi.org/10.1186/s12964-024-01659-x.

[327]

Y. N. Li, C. W. Chen, T. Trinh-Minh, et al., “Dynamic Changes in O-Glcnacylation Regulate Osteoclast Differentiation and Bone Loss via Nucleoporin 153,” Bone Research 10, no. 1 (2022): 51, https://doi.org/10.1038/s41413-022-00218-9.

[328]

H. B. Kim, S. W. Lee, C. H. Mun, et al., “O-Linked N-Acetylglucosamine Glycosylation of P65 Aggravated the Inflammation in both Fibroblast-Like Synoviocytes Stimulated by Tumor Necrosis Factor-Alpha and Mice With Collagen Induced Arthritis,” Arthritis Research & Therapy 17, no. 1 (2015): 248, https://doi.org/10.1186/s13075-015-0762-7.

[329]

C. Jacques, I. Floris, and B. Lejeune, “Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds With One Stone as the Rationale of the 2Larth((R)) Micro-Immunotherapy Treatment,” International Journal of Molecular Sciences 22, no. 13 (2021), https://doi.org/10.3390/ijms22136717.

[330]

N. Huang, H. Dong, Y. Luo, et al., “Th17 Cells in Periodontitis and Its Regulation by a20,” Frontiers in Immunology 12 (2021): 742925, https://doi.org/10.3389/fimmu.2021.742925.

[331]

M. Machacek, H. Saunders, Z. Zhang, et al., “Elevated O-Glcnacylation Enhances Pro-Inflammatory Th17 Function by Altering the Intracellular Lipid Microenvironment,” Journal of Biological Chemistry 294, no. 22 (2019): 8973–8990, https://doi.org/10.1074/jbc.RA119.008373.

[332]

[333]

D. K. Shah and J. C. Zuniga-Pflucker, “An Overview of the Intrathymic Intricacies of T Cell Development,” Journal of Immunology 192, no. 9 (2014): 4017–4023, https://doi.org/10.4049/jimmunol.1302259.

[334]

M. Swamy, S. Pathak, K. M. Grzes, et al., “Glucose and Glutamine Fuel Protein O-Glcnacylation to Control T Cell Self-Renewal and Malignancy,” Nature Immunology 17, no. 6 (2016): 712–720, https://doi.org/10.1038/ni.3439.

[335]

N. O'Donnell, N. E. Zachara, G. W. Hart, et al., “Ogt-Dependent X-Chromosome-Linked Protein Glycosylation Is a Requisite Modification in Somatic Cell Function and Embryo Viability,” Molecular and Cellular Biology 24, no. 4 (2004): 1680–1690, https://doi.org/10.1128/MCB.24.4.1680-1690.2004.

[336]

L. K. Abramowitz and J. A. Hanover, “T Cell Development and the Physiological Role of O-Glcnac,” Febs Letters 592, no. 23 (2018): 3943–3949, https://doi.org/10.1002/1873-3468.13159.

[337]

M. D. Buck, D. O'Sullivan, and E. L. Pearce, “T Cell Metabolism Drives Immunity,” Journal of Experimental Medicine 212, no. 9 (2015): 1345–1360, https://doi.org/10.1084/jem.20151159.

[338]

[339]

A. Golks, T. T. Tran, J. F. Goetschy, et al., “Requirement for O-Linked N-Acetylglucosaminyltransferase in Lymphocytes Activation,” Embo Journal 26, no. 20 (2007): 4368–4379, https://doi.org/10.1038/sj.emboj.7601845.

[340]

P. J. Lund, J. E. Elias, and M. M. Davis, “Global Analysis of O-Glcnac Glycoproteins in Activated Human T Cells,” Journal of Immunology 197, no. 8 (2016): 3086–3098, https://doi.org/10.4049/jimmunol.1502031.

[341]

L. K. Abramowitz, S. S. Olivier-Van, and J. A. Hanover, “Chromosome Imbalance as a Driver of Sex Disparity in Disease,” Journal of Genomics 2 (2014): 77–88, https://doi.org/10.7150/jgen.8123.

[342]

P. Ramakrishnan, P. M. Clark, D. E. Mason, et al., “Activation of the Transcriptional Function of the Nf-Kappab Protein C-Rel by O-Glcnac Glycosylation,” Science Signaling 6, no. 290 (2013): ra75, https://doi.org/10.1126/scisignal.2004097.

[343]

[344]

Y. Yuan, L. Wang, D. Ge, et al., “Exosomal O-Glcnac Transferase from Esophageal Carcinoma Stem Cell Promotes Cancer Immunosuppression Through Up-Regulation of Pd-1 in Cd8(+) T Cells,” Cancer Letters 500 (2021): 98–106, https://doi.org/10.1016/j.canlet.2020.12.012.

[345]

J. L. Wu, M. F. Chiang, P. H. Hsu, et al., “O-Glcnacylation Is Required for B Cell Homeostasis and Antibody Responses,” Nature Communications 8, no. 1 (2017): 1854, https://doi.org/10.1038/s41467-017-01677-z.

[346]

B. Schiemann, J. L. Gommerman, K. Vora, et al., “An Essential Role for Baff in the Normal Development of B Cells Through a Bcma-Independent Pathway,” Science 293, no. 5537 (2001): 2111–2114, https://doi.org/10.1126/science.1061964.

[347]

Y. Sasaki, S. Casola, J. L. Kutok, et al., “Tnf Family Member B Cell-Activating Factor (Baff) Receptor-Dependent and -Independent Roles for Baff in B Cell Physiology,” Journal of Immunology 173, no. 4 (2004): 2245–2252, https://doi.org/10.4049/jimmunol.173.4.2245.

[348]

[349]

F. Mackay, W. A. Figgett, D. Saulep, et al., “B-Cell Stage and Context-Dependent Requirements for Survival Signals from Baff and the B-Cell Receptor,” Immunological Reviews 237, no. 1 (2010): 205–225, https://doi.org/10.1111/j.1600-065X.2010.00944.x.

[350]

D. F. Allison, J. J. Wamsley, M. Kumar, et al., “Modification of Rela by O-Linked N-Acetylglucosamine Links Glucose Metabolism to Nf-Kappab Acetylation and Transcription,” Proceedings of the National Academy of Sciences of the United States of America 109, no. 42 (2012): 16888–16893, https://doi.org/10.1073/pnas.1208468109.

[351]

X. Li, Z. Zhang, L. Li, et al., “Myeloid-Derived Cullin 3 Promotes Stat3 Phosphorylation by Inhibiting Ogt Expression and Protects against Intestinal Inflammation,” Journal of Experimental Medicine 214, no. 4 (2017): 1093–1109, https://doi.org/10.1084/jem.20161105.

[352]

K. J. Staples, T. Smallie, L. M. Williams, et al., “Il-10 Induces Il-10 in Primary Human Monocyte-Derived Macrophages via the Transcription Factor Stat3,” Journal of Immunology 178, no. 8 (2007): 4779–4785, https://doi.org/10.4049/jimmunol.178.8.4779.

[353]

K. Takeda, B. E. Clausen, T. Kaisho, et al., “Enhanced Th1 Activity and Development of Chronic Enterocolitis in Mice Devoid of Stat3 in Macrophages and Neutrophils,” Immunity 10, no. 1 (1999): 39–49, https://doi.org/10.1016/S1074-7613(00)80005-9.

[354]

S. Bugide, M. R. Green, and N. Wajapeyee, “Inhibition of Enhancer of Zeste Homolog 2 (Ezh2) Induces Natural Killer Cell-Mediated Eradication of Hepatocellular Carcinoma Cells,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 15 (2018): E3509–E3518.

[355]

J. Yin, J. W. Leavenworth, Y. Li, et al., “Ezh2 Regulates Differentiation and Function of Natural Killer Cells Through Histone Methyltransferase Activity,” Proceedings of the National Academy of Sciences of the United States of America 112, no. 52 (2015): 15988–15993, https://doi.org/10.1073/pnas.1521740112.

[356]

[357]

Y. H. Chang, C. L. Weng, and K. I. Lin, “O-Glcnacylation and Its Role in the Immune System,” Journal of Biomedical Science 27, no. 1 (2020): 57, https://doi.org/10.1186/s12929-020-00648-9.

[358]

Y. Deng, Y. Kerdiles, J. Chu, et al., “Transcription Factor Foxo1 Is a Negative Regulator of Natural Killer Cell Maturation and Function,” Immunity 42, no. 3 (2015): 457–470, https://doi.org/10.1016/j.immuni.2015.02.006.

[359]

S. Lenzen and U. Panten, “Alloxan: History and Mechanism of Action,” Diabetologia 31, no. 6 (1988): 337–342, https://doi.org/10.1007/BF02341500.

[360]

S. Lenzen and U. Panten, “Alloxan: History and Mechanism of Action,” Diabetologia 31, no. 6 (1988): 337–342, https://doi.org/10.1007/BF02341500.

[361]

M. S. Macauley, G. E. Whitworth, A. W. Debowski, et al., “O-Glcnacase Uses Substrate-Assisted Catalysis: Kinetic Analysis and Development of Highly Selective Mechanism-Inspired Inhibitors,” Journal of Biological Chemistry 280, no. 27 (2005): 25313–25322, https://doi.org/10.1074/jbc.M413819200.

[362]

R. J. Konrad, F. Zhang, J. E. Hale, et al., “Alloxan Is an Inhibitor of the Enzyme O-Linked N-Acetylglucosamine Transferase,” Biochemical and Biophysical Research Communications 293, no. 1 (2002): 207–212, https://doi.org/10.1016/S0006-291X(02)00200-0.

[363]

J. Liu, Y. Yu, Y. Z. Fan, et al., “Cardiovascular Effects of Endomorphins in Alloxan-Induced Diabetic Rats,” Peptides 26, no. 4 (2005): 607–614, https://doi.org/10.1016/j.peptides.2004.11.017.

[364]

H. Zhang, G. Gao, and U. T. Brunk, “Extracellular Reduction of Alloxan Results in Oxygen Radical-Mediated Attack on Plasma and Lysosomal Membranes,” Apmis 100, no. 4 (1992): 317–325, https://doi.org/10.1111/j.1699-0463.1992.tb00878.x.

[365]

V. Kapuria, U. F. Rohrig, P. Waridel, et al., “The Conserved Threonine-Rich Region of the Hcf-1(Pro) Repeat Activates Promiscuous Ogt:Udp-Glcnac Glycosylation and Proteolysis Activities,” Journal of Biological Chemistry 293, no. 46 (2018): 17754–17768, https://doi.org/10.1074/jbc.RA118.004185.

[366]

T. W. Liu, W. F. Zandberg, T. M. Gloster, et al., “Metabolic Inhibitors of O-Glcnac Transferase That Act in Vivo Implicate Decreased O-Glcnac Levels in Leptin-Mediated Nutrient Sensing,” Angewandte Chemie-International Edition 57, no. 26 (2018): 7644–7648, https://doi.org/10.1002/anie.201803254.

[367]

T. M. Gloster, W. F. Zandberg, J. E. Heinonen, et al., “Hijacking a Biosynthetic Pathway Yields a Glycosyltransferase Inhibitor Within Cells,” Nature Chemical Biology 7, no. 3 (2011): 174–181, https://doi.org/10.1038/nchembio.520.

[368]

T. F. Wang, Z. Q. Feng, Y. W. Sun, et al., “Disruption of O-Glcnacylation Homeostasis Induced Ovarian Granulosa Cell Injury in Bovine,” International Journal of Molecular Sciences 23, no. 14 (2022), https://doi.org/10.3390/ijms23147815.

[369]

R. S. Haltiwanger, K. Grove, and G. A. Philipsberg, “Modulation of O-Linked N-Acetylglucosamine Levels on Nuclear and Cytoplasmic Proteins in Vivo Using the Peptide O-Glcnac-Beta-N-Acetylglucosaminidase Inhibitor O-(2-Acetamido-2-Deoxy-D-Glucopyranosylidene)Amino-N-Phenylcarbamate,” Journal of Biological Chemistry 273, no. 6 (1998): 3611–3617, https://doi.org/10.1074/jbc.273.6.3611.

[370]

[371]

L. R. James, D. Tang, A. Ingram, et al., “Flux Through the Hexosamine Pathway Is a Determinant of Nuclear Factor Kappab- Dependent Promoter Activation,” Diabetes 51, no. 4 (2002): 1146–1156, https://doi.org/10.2337/diabetes.51.4.1146.

[372]

S. Hennebicq-Reig, T. Lesuffleur, C. Capon, et al., “Permanent Exposure of Mucin-Secreting Ht-29 Cells to Benzyl-N-Acetyl-Alpha-D-Galactosaminide Induces Abnormal O-Glycosylation of Mucins and Inhibits Constitutive and Stimulated Muc5Ac Secretion,” Biochemical Journal 334, no. Pt 1 (1998): 283–295, https://doi.org/10.1042/bj3340283.

[373]

S. S. Olivier-Van, L. Drougat, V. Dehennaut, et al., “Serum-Stimulated Cell Cycle Entry Promotes Ncogt Synthesis Required for Cyclin D Expression,” Oncogenesis 1, no. 12 (2012): e36, https://doi.org/10.1038/oncsis.2012.36.

[374]

[375]

[376]

V. V. Lima, F. R. Giachini, F. S. Carneiro, et al., “O-Glcnacylation Contributes to the Vascular Effects of Et-1 via Activation of the Rhoa/Rho-Kinase Pathway,” Cardiovascular Research 89, no. 3 (2011): 614–622, https://doi.org/10.1093/cvr/cvq338.

[377]

R. Trapannone, K. Rafie, and D. M. van Aalten, “O-Glcnac Transferase Inhibitors: Current Tools and Future Challenges,” Biochemical Society Transactions 44, no. 1 (2016): 88–93, https://doi.org/10.1042/BST20150189.

[378]

K. Rafie, A. Gorelik, R. Trapannone, et al., “Thio-Linked Udp-Peptide Conjugates as O-Glcnac Transferase Inhibitors,” Bioconjugate Chemistry 29, no. 6 (2018): 1834–1840, https://doi.org/10.1021/acs.bioconjchem.8b00194.

[379]

B. J. Gross, B. C. Kraybill, and S. Walker, “Discovery of O-Glcnac Transferase Inhibitors,” Journal of the American Chemical Society 127, no. 42 (2005): 14588–14589, https://doi.org/10.1021/ja0555217.

[380]

[381]

S. Rehman, A. Obaid, A. Naz, et al., “Model-Based in Silico Analysis of the Pi3K/Akt Pathway: The Elucidation of Cross-Talk between Diabetes and Breast Cancer,” Peerj 6 (2018): e5917, https://doi.org/10.7717/peerj.5917.

[382]

J. Jiang, M. B. Lazarus, L. Pasquina, et al., “A Neutral Diphosphate Mimic Crosslinks the Active Site of Human O-Glcnac Transferase,” Nature Chemical Biology 8, no. 1 (2011): 72–77, https://doi.org/10.1038/nchembio.711.

[383]

Y. Yang, Y. Yan, J. Yin, et al., “O-Glcnacylation of Ythdf2 Promotes Hbv-Related Hepatocellular Carcinoma Progression in an N(6)-Methyladenosine-Dependent Manner,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 63, https://doi.org/10.1038/s41392-023-01316-8.

[384]

Y. K. Wu, M. Liu, H. L. Zhou, et al., “O-Linked Beta-N-Acetylglucosamine Transferase Regulates Macrophage Polarization in Diabetic Periodontitis: In Vivo and in Vitro Study,” World Journal of Diabetes 16, no. 3 (2025): 95092, https://doi.org/10.4239/wjd.v16.i3.95092.

[385]

H. M. Itkonen, A. Urbanucci, S. E. Martin, et al., “High Ogt Activity Is Essential for Myc-Driven Proliferation of Prostate Cancer Cells,” Theranostics 9, no. 8 (2019): 2183–2197, https://doi.org/10.7150/thno.30834.

[386]

[387]

[388]

[389]

R. F. Ortiz-Meoz, J. Jiang, M. B. Lazarus, et al., “A Small Molecule That Inhibits Ogt Activity in Cells,” Acs Chemical Biology 10, no. 6 (2015): 1392–1397, https://doi.org/10.1021/acschembio.5b00004.

[390]

V. S. Borodkin, M. Schimpl, M. Gundogdu, et al., “Bisubstrate Udp-Peptide Conjugates as Human O-Glcnac Transferase Inhibitors,” Biochemical Journal 457, no. 3 (2014): 497–502, https://doi.org/10.1042/BJ20131272.

[391]

Y. Song, “Catch in Nucleus,” Nature Chemical Biology 19, no. 11 (2023): 1291, https://doi.org/10.1038/s41589-023-01470-8.

[392]

M. Villagrasa, M. Guillamon, A. Navarro, et al., “Development of a Pressurized Liquid Extraction-Solid-Phase Extraction Followed by Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry Method for the Quantitative Determination of Benzoxazolinones and Their Degradation Products in Agricultural Soil,” Journal of Chromatography A 1179, no. 2 (2008): 190–197.

[393]

Q. Zhou, M. Yang, J. Fu, et al., “Kif1a Promotes Neuroendocrine Differentiation in Prostate Cancer by Regulating the Ogt-Mediated O-Glcnacylation,” Cell Death & Disease 15, no. 11 (2024): 796, https://doi.org/10.1038/s41419-024-07142-2.

[394]

[395]

N. S. Sharma, V. K. Gupta, P. Dauer, et al., “O-Glcnac Modification of Sox2 Regulates Self-Renewal in Pancreatic Cancer by Promoting Its Stability,” Theranostics 9, no. 12 (2019): 3410–3424, https://doi.org/10.7150/thno.32615.

[396]

C. Zhang, X. Yin, J. Jiang, et al., “Downregulation of Gfpt2 Enhances Cisplatin Chemotherapy Sensitivity in Stk11/Kras Mutant Non-Small Cell Lung Cancer by Regulating the Hexosamine Biosynthesis Pathway, Resisting Tumor Growth,” Cytokine 191 (2025): 156943, https://doi.org/10.1016/j.cyto.2025.156943.

[397]

V. Makwana, A. S. Dukie, and S. Rudrawar, “Investigating the Impact of Ogt Inhibition on Doxorubicin- And Docetaxel-Induced Cytotoxicity in Pc-3 and Wpmy-1 Cells,” International Journal of Toxicology 39, no. 6 (2020): 586–593, https://doi.org/10.1177/1091581820948433.

[398]

D. E. Lee, G. Y. Lee, H. M. Lee, et al., “Synergistic Apoptosis by Combination of Metformin and an O-Glcnacylation Inhibitor in Colon Cancer Cells,” Cancer Cell International 23, no. 1 (2023): 108, https://doi.org/10.1186/s12935-023-02954-2.

[399]

I. Loison, A. Pioger, S. Paget, et al., “O-Glcnacylation Inhibition Redirects the Response of Colon Cancer Cells to Chemotherapy from Senescence to Apoptosis,” Cell Death & Disease 15, no. 10 (2024): 762, https://doi.org/10.1038/s41419-024-07131-5.

[400]

S. J. Lee, D. E. Lee, S. Y. Choi, et al., “Osmi-1 Enhances Trail-Induced Apoptosis Through Er Stress and Nf-Kappab Signaling in Colon Cancer Cells,” International Journal of Molecular Sciences 22, no. 20 (2021), https://doi.org/10.3390/ijms222011073.

[401]

S. J. Lee and O. S. Kwon, “O-Glcnac Transferase Inhibitor Synergistically Enhances Doxorubicin-Induced Apoptosis in Hepg2 Cells,” Cancers 12, no. 11 (2020), https://doi.org/10.3390/cancers12113154.

[402]

B. Lin, S. Chai, Q. Zhang, et al., “Sialic Acid-Modified O-Glcnac Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma,” Molecular Pharmaceutics 21, no. 1 (2024): 102–112, https://doi.org/10.1021/acs.molpharmaceut.3c00451.

[403]

J. Lee, G. B. Koo, J. Park, et al., “Downregulation of O-Glcnacylation Enhances Etoposide-Induced P53-Mediated Apoptosis in Hepg2 Human Liver Cancer Cells,” Febs Open Bio 15, no. 7 (2025): 1176–1188, https://doi.org/10.1002/2211-5463.70028.

[404]

J. Wu, Z. Tan, H. Li, et al., “Melatonin Reduces Proliferation and Promotes Apoptosis of Bladder Cancer Cells by Suppressing O-Glcnacylation of Cyclin-Dependent-Like Kinase 5,” Journal of Pineal Research 71, no. 3 (2021): e12765, https://doi.org/10.1111/jpi.12765.

[405]

S. Lu, Z. Liao, X. Lu, et al., “Hyperglycemia Acutely Increases Cytosolic Reactive Oxygen Species via O-Linked Glcnacylation and Camkii Activation in Mouse Ventricular Myocytes,” Circulation Research 126, no. 10 (2020): e80–e96, https://doi.org/10.1161/CIRCRESAHA.119.316288.

[406]

G. E. Whitworth, M. S. Macauley, K. A. Stubbs, et al., “Analysis of Pugnac and Nag-Thiazoline as Transition State Analogues for Human O-Glcnacase: Mechanistic and Structural Insights into Inhibitor Selectivity and Transition State Poise,” Journal of the American Chemical Society 129, no. 3 (2007): 635–644, https://doi.org/10.1021/ja065697o.

[407]

S. Y. Park, J. Ryu, and W. Lee, “O-Glcnac Modification on Irs-1 and Akt2 by Pugnac Inhibits Their Phosphorylation and Induces Insulin Resistance in Rat Primary Adipocytes,” Experimental and Molecular Medicine 37, no. 3 (2005): 220–229, https://doi.org/10.1038/emm.2005.30.

[408]

W. Zhou, Q. Tang, S. Wang, et al., “Local Thiamet-G Delivery by a Thermosensitive Hydrogel Confers Ischemic Cardiac Repair via Myeloid M2-Like Activation in a Stat6 O-Glcnacylation-Dependent Manner,” International Immunopharmacology 131 (2024): 111883, https://doi.org/10.1016/j.intimp.2024.111883.

[409]

[410]

M. Denis, T. Dupas, A. Persello, et al., “An O-Glcnacylomic Approach Reveals Acly as a Potential Target in Sepsis in the Young Rat,” International Journal of Molecular Sciences 22, no. 17 (2021), https://doi.org/10.3390/ijms22179236.

[411]

A. Adibekian, B. R. Martin, C. Wang, et al., “Click-Generated Triazole Ureas as Ultrapotent in Vivo-Active Serine Hydrolase Inhibitors,” Nature Chemical Biology 7, no. 7 (2011): 469–478, https://doi.org/10.1038/nchembio.579.

[412]

R. Wieboldt and H. Laubli, “Glycosaminoglycans in Cancer Therapy,” American Journal of Physiology-Cell Physiology 322, no. 6 (2022): C1187–C1200, https://doi.org/10.1152/ajpcell.00063.2022.

[413]

H. C. Dorfmueller, V. S. Borodkin, M. Schimpl, et al., “Glcnacstatins Are Nanomolar Inhibitors of Human O-Glcnacase Inducing Cellular Hyper-O-Glcnacylation,” Biochemical Journal 420, no. 2 (2009): 221–227, https://doi.org/10.1042/BJ20090110.

[414]

H. C. Dorfmueller, V. S. Borodkin, M. Schimpl, et al., “Glcnacstatin: A Picomolar, Selective O-Glcnacase Inhibitor That Modulates Intracellular O-Glcnacylation Levels,” Journal of the American Chemical Society 128, no. 51 (2006): 16484–16485, https://doi.org/10.1021/ja066743n.

[415]

[416]

[417]

R. Herzog, T. O. Bender, A. Vychytil, et al., “Dynamic O-Linked N-Acetylglucosamine Modification of Proteins Affects Stress Responses and Survival of Mesothelial Cells Exposed to Peritoneal Dialysis Fluids,” Journal of the American Society of Nephrology 25, no. 12 (2014): 2778–2788, https://doi.org/10.1681/ASN.2013101128.

[418]

[419]

H. C. Dorfmueller, V. S. Borodkin, M. Schimpl, et al., “Cell-Penetrant, Nanomolar O-Glcnacase Inhibitors Selective against Lysosomal Hexosaminidases,” Chemistry & Biology 17, no. 11 (2010): 1250–1255, https://doi.org/10.1016/j.chembiol.2010.09.014.

[420]

V. I. Ivanov and M. Y. Karpeisky, “Dynamic Three-Dimensional Model for Enzymic Transamination,” Advances in Enzymology and Related Areas of Molecular Biology 32 (1969): 21–53.

[421]

G. L. Coffey, J. Ehrlich, M. W. Fisher, et al., “6-Diazo-5-Oxo-L-Norleucine, a New Tumor-Inhibitory Substance. I. Biologic Studies,” Antibiotics and Chemotherapy (Northfield) 6, no. 8 (1956): 487–497.

[422]

C. C. Stock, H. C. Reilly, S. M. Buckley, et al., “Azaserine, a New Tumour-Inhibitory Substance; Studies With Crocker Mouse Sarcoma 180,” Nature 173, no. 4393 (1954): 71–72.

[423]

K. E. Wellen, C. Lu, A. Mancuso, et al., “The Hexosamine Biosynthetic Pathway Couples Growth Factor-Induced Glutamine Uptake to Glucose Metabolism,” Genes & Development 24, no. 24 (2010): 2784–2799, https://doi.org/10.1101/gad.1985910.

[424]

R. Rais, A. Jancarik, L. Tenora, et al., “Discovery of 6-Diazo-5-Oxo-L-Norleucine (Don) Prodrugs With Enhanced Csf Delivery in Monkeys: A Potential Treatment for Glioblastoma,” Journal of Medicinal Chemistry 59, no. 18 (2016): 8621–8633, https://doi.org/10.1021/acs.jmedchem.6b01069.

[425]

A. Le, A. N. Lane, M. Hamaker, et al., “Glucose-Independent Glutamine Metabolism via Tca Cycling for Proliferation and Survival in B Cells,” Cell Metabolism 15, no. 1 (2012): 110–121, https://doi.org/10.1016/j.cmet.2011.12.009.

[426]

I. O. Bolanle, K. Riches-Suman, R. Williamson, et al., “Emerging Roles of Protein O-Glcnacylation in Cardiovascular Diseases: Insights and Novel Therapeutic Targets,” Pharmacological Research 165 (2021): 105467, https://doi.org/10.1016/j.phrs.2021.105467.

[427]

A. Olvera, J. P. Martinez, M. Casadella, et al., “Benzyl-2-Acetamido-2-Deoxy-Alpha-D-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy in Vitro,” Frontiers in Immunology 8 (2017): 2010, https://doi.org/10.3389/fimmu.2017.02010.

[428]

[429]

[430]

[431]

Z. Xun, T. Li, and X. Xue, “The Application Strategy of Liposomes in Organ Targeting Therapy,” Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology 16, no. 2 (2024): e1955, https://doi.org/10.1002/wnan.1955.

[432]

H. Yu, F. Jin, D. Liu, et al., “Ros-Responsive Nano-Drug Delivery System Combining Mitochondria-Targeting Ceria Nanoparticles With Atorvastatin for Acute Kidney Injury,” Theranostics 10, no. 5 (2020): 2342–2357, https://doi.org/10.7150/thno.40395.

[433]

R. Bruni, P. Possenti, C. Bordignon, et al., “Ultrasmall Polymeric Nanocarriers for Drug Delivery to Podocytes in Kidney Glomerulus,” Journal of Controlled Release 255 (2017): 94–107, https://doi.org/10.1016/j.jconrel.2017.04.005.

[434]

X. Lai, X. Geng, L. Tan, et al., “A Ph-Responsive System Based on Fluorescence Enhanced Gold Nanoparticles for Renal Targeting Drug Delivery and Fibrosis Therapy,” International Journal of Nanomedicine 15 (2020): 5613–5627, https://doi.org/10.2147/IJN.S260069.

[435]

H. Qiao, M. Sun, Z. Su, et al., “Kidney-Specific Drug Delivery System for Renal Fibrosis Based on Coordination-Driven Assembly of Catechol-Derived Chitosan,” Biomaterials 35, no. 25 (2014): 7157–7171, https://doi.org/10.1016/j.biomaterials.2014.04.106.

[436]

L. Guo, S. Luo, Z. Du, et al., “Targeted Delivery of Celastrol to Mesangial Cells Is Effective against Mesangioproliferative Glomerulonephritis,” Nature Communications 8, no. 1 (2017): 878, https://doi.org/10.1038/s41467-017-00834-8.

[437]

D. Chen, S. Han, Y. Zhu, et al., “Kidney-Targeted Drug Delivery via Rhein-Loaded Polyethyleneglycol-Co-Polycaprolactone-Co-Polyethylenimine Nanoparticles for Diabetic Nephropathy Therapy,” International Journal of Nanomedicine 13 (2018): 3507–3527, https://doi.org/10.2147/IJN.S166445.

[438]

R. M. Williams, J. Shah, B. D. Ng, et al., “Mesoscale Nanoparticles Selectively Target the Renal Proximal Tubule Epithelium,” Nano Letters 15, no. 4 (2015): 2358–2364, https://doi.org/10.1021/nl504610d.

[439]

S. J. Han, R. M. Williams, V. D'Agati, et al., “Selective Nanoparticle-Mediated Targeting of Renal Tubular Toll-Like Receptor 9 Attenuates Ischemic Acute Kidney Injury,” Kidney International 98, no. 1 (2020): 76–87, https://doi.org/10.1016/j.kint.2020.01.036.

[440]

S. Liu, M. Zhao, Y. Zhou, et al., “A Self-Assembling Peptide Hydrogel-Based Drug Co-Delivery Platform to Improve Tissue Repair after Ischemia-Reperfusion Injury,” Acta Biomaterialia 103 (2020): 102–114, https://doi.org/10.1016/j.actbio.2019.12.011.

[441]

M. Gu, L. Lu, Q. Wei, et al., “Improved Oral Bioavailability and Anti-Chronic Renal Failure Activity of Chrysophanol via Mixed Polymeric Micelles,” Journal of Microencapsulation 38, no. 1 (2021): 47–60, https://doi.org/10.1080/02652048.2020.1849440.

[442]

Z. Binkhathlan, R. Ali, W. Qamar, et al., “Pharmacokinetic and Tissue Distribution of Orally Administered Cyclosporine a-Loaded Poly(Ethylene Oxide)-Block-Poly(Epsilon-Caprolactone) Micelles versus Sandimmune((R)) in Rats,” Pharmaceutical Research 38, no. 1 (2021): 51–65, https://doi.org/10.1007/s11095-021-02990-5.

[443]

X. Qin, Y. Xu, X. Zhou, et al., “An Injectable Micelle-Hydrogel Hybrid for Localized and Prolonged Drug Delivery in the Management of Renal Fibrosis,” Acta Pharmaceutica Sinica B 11, no. 3 (2021): 835–847, https://doi.org/10.1016/j.apsb.2020.10.016.

[444]

H. Katsumi, R. Takashima, H. Suzuki, et al., “S-Nitrosylated L-Serine-Modified Dendrimer as a Kidney-Targeting Nitric Oxide Donor for Prevention of Renal Ischaemia/Reperfusion Injury,” Free Radical Research 54, no. 11–12 (2020): 841–847, https://doi.org/10.1080/10715762.2019.1697437.

[445]

H. Kobayashi, S. K. Jo, S. Kawamoto, et al., “Polyamine Dendrimer-Based Mri Contrast Agents for Functional Kidney Imaging to Diagnose Acute Renal Failure,” Journal of Magnetic Resonance Imaging 20, no. 3 (2004): 512–518, https://doi.org/10.1002/jmri.20147.

[446]

W. Y. Ding, V. Kuzmuk, S. Hunter, et al., “Adeno-Associated Virus Gene Therapy Prevents Progression of Kidney Disease in Genetic Models of Nephrotic Syndrome,” Science Translational Medicine 15, no. 708 (2023): eabc8226, https://doi.org/10.1126/scitranslmed.abc8226.

[447]

M. Haas, A. C. Kluppel, E. S. Wartna, et al., “Drug-Targeting to the Kidney: Renal Delivery and Degradation of a Naproxen-Lysozyme Conjugate in Vivo,” Kidney International 52, no. 6 (1997): 1693–1699, https://doi.org/10.1038/ki.1997.504.

[448]

X. Pan, F. Xie, D. Xiao, et al., “Design, Synthesis, and Renal Targeting of Methylprednisolone-Lysozyme,” International Journal of Molecular Sciences 21, no. 6 (2020), https://doi.org/10.3390/ijms21061922.

[449]

M. E. Dolman, M. M. Fretz, G. J. Segers, et al., “Renal Targeting of Kinase Inhibitors,” International Journal of Pharmaceutics 364, no. 2 (2008): 249–257, https://doi.org/10.1016/j.ijpharm.2008.04.040.

[450]

X. P. Zheng, Q. Nie, J. Feng, et al., “Kidney-Targeted Baicalin-Lysozyme Conjugate Ameliorates Renal Fibrosis in Rats With Diabetic Nephropathy Induced by Streptozotocin,” Bmc Nephrology 21, no. 1 (2020): 174, https://doi.org/10.1186/s12882-020-01833-6.

[451]

G. R. Bidwell, I. Fokt, W. Priebe, et al., “Development of Elastin-Like Polypeptide for Thermally Targeted Delivery of Doxorubicin,” Biochemical Pharmacology 73, no. 5 (2007): 620–631, https://doi.org/10.1016/j.bcp.2006.10.028.

[452]

M. Kuna, F. Mahdi, A. R. Chade, et al., “Molecular Size Modulates Pharmacokinetics, Biodistribution, and Renal Deposition of the Drug Delivery Biopolymer Elastin-Like Polypeptide,” Scientific Reports 8, no. 1 (2018): 7923, https://doi.org/10.1038/s41598-018-24897-9.

[453]

X. Wang, Y. Lin, Y. Zeng, et al., “Effects of Mycophenolic Acid-Glucosamine Conjugates on the Base of Kidney Targeted Drug Delivery,” International Journal of Pharmaceutics 456, no. 1 (2013): 223–234, https://doi.org/10.1016/j.ijpharm.2013.07.064.

[454]

Z. X. Yuan, X. Sun, T. Gong, et al., “Randomly 50% N-Acetylated Low Molecular Weight Chitosan as a Novel Renal Targeting Carrier,” Journal of Drug Targeting 15, no. 4 (2007): 269–278, https://doi.org/10.1080/10611860701289875.

[455]

S. Shang, X. Li, H. Wang, et al., “Targeted Therapy of Kidney Disease With Nanoparticle Drug Delivery Materials,” Bioactive Materials 37 (2024): 206–221, https://doi.org/10.1016/j.bioactmat.2024.03.014.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.